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Schwann cells offer great promise in treating peripheral nerve injuries as they can 
assist in clearing debris, provide trophic support, and importantly, remyelinate 
regenerating axons, but there are no readily available sources of primary Schwann cells 
for peripheral nerve cell therapies. While Schwann cell-like cells have been derived from 
e.g. embryonic stem cells, mesenchymal stem cells and skin-derived precursors, these 
cells have yet to show significant myelination activity compared to primary Schwann 
cells. This is the main hurdle for their utility in cell-based nerve regenerative therapies.  
Cell reprogramming has opened up the possibility to derive Schwann cell progenitors 
from accessible sources. A critical challenge however remains in achieving high 
functionality in these cells. The use of transcription factor overexpression, typically 
achieved using viral vectors, is a promising method of directing cell fate and enhancing 
cell maturation.  However, risks associated with viral vectors limit their utility in future 
clinical applications.  In my thesis dissertation, a polymer-based nanoparticle transfection 
method for overexpression of transcription factors and other genes of interest in human 
pluripotent stem cell-derived Schwann cell precursors was developed.  After screening 
candidate transcription factors, overexpression of Egr2 was shown to enhance the 
myelination frequency of primary rat Schwann cells. To expand the cell types for 
supporting peripheral nerve regeneration, oligodendrocyte progenitor cells found in the 
central nervous system were shown to survive and function in a peripheral nerve injury 
model.  These results demonstrated for the first time that oligodendrocyte progenitor cells 
survive heterotopic engraftment to the peripheral nervous system, and transdifferentiate 
into a Schwann cell-like phenotype capable of remyelinating regenerating axons. thus 
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supporting the oligodendrocyte progenitor cells as a new candidate cell type for 
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CHAPTER 1 - PERIPHERAL NERVE REGENERATION 
AND CELL THERAPIES 
This dissertation is motivated by two facts regarding peripheral nerve 
regeneration.  The first is that it exists; the peripheral nervous system (PNS) has an 
intrinsic capability to regenerate.  This is manifested for instance by surgical techniques 
that now allow for hand, forearm, and face transplantations with accompanied functional 
recovery, of which over 100 cases have been reported to date1.  This sets the PNS apart 
from the central nervous system (CNS), which lacks many of the features enabling 
regeneration in the PNS, with an injury response that impedes axonal regrowth through 
the injured and scarred tissue.  The second fact that is the basis of this dissertation is that 
the regeneration is typically incomplete, lacks the necessary specificity and functional 
recovery, and is highly dependent on the type of injury, nerves affected, distance to the 
target tissue, and the timing of the surgical intervention2.   
In this chapter, we will first discuss general mechanisms of PNS regeneration, as 
they are understood today, and some of the main challenges that hinder complete 
functional regeneration.  We will highlight the role of the Schwann cells (SCs), the cell 
type in focus of this dissertation, in the context of its PNS regeneration.  We will contrast 
the pro-regenerative response of the PNS to the injury response of the CNS to highlight 
some key aspects necessary for nerve regeneration to occur. Understanding these aspects 
may allow extending results related to the approach presented in Chapter 4 into 
regenerative therapies for the PNS and the CNS both.  We will then go into greater detail 
regarding SC development, which is important to understand, as we will be dealing with 
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stem cell-based approaches for generating these cells.  Cell reprogramming techniques 
will be reviewed in order to understand the capabilities and challenges of methods 
underlying the cell preparations that we are working with.  Finally, the state-of-the-art 
regarding stem cell-based approaches in PNS regeneration will be reviewed, highlighting 
the need for and difficulty in deriving fully functional and mature SCs.  As these concepts 
are interconnected, please excuse some overlap between the sections. 
1.1 Peripheral nerve regeneration mechanisms 
Injuries to nerves in the PNS will lead to the activation and recruitment of a 
number of cell types.  First, the affected neurons will switch from their normal signaling 
phenotype to a regeneration phenotype with the upregulation of multiple regeneration 
associated genes3.  They form endbulbs at the end of their severed axons, at which local 
peptide translation and secretion takes place4.  An example of this is the local expression 
of calcitonin gene-related peptide (CGRP), which may act as a vasodilator5,6, but also 
becomes a SC mitogen7. 
SCs become activated and transdifferentiate into a repair phenotype8-10 (reviewed 
by Jessen and Mirsky11).  Myelinating SCs associated with the severed axons will initiate 
myelin clearance through autophagocytosis of their own myelin components12,13.  The 
activation is not only seen in myelinating SCs of injured axons, but also in non-
myelinating SCs of nearby tissue11,14,15.  The activated SCs will play a large part in the 
repair process through secretion of trophic factors and cytokines.  These will both 
promote the survival of neurons, guide their regrowth, and recruit macrophages to clear 
debris16-21.  Recruited macrophages will react to the hypoxic environment at the injury 
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site and secrete VEGF-A to attract endothelial cells.  These endothelial cells together 
with fibroblasts in turn guide the activated SCs, along which regenerating axons follow22-
24.  Where basal lamina still remains intact from previous axonal tracts in the distal nerve, 
SCs will obtain a bipolar, elongated morphology that helps guide axons.  These structures 
are called bands of Büngner25,26.  SCs produce extracellular matrix components such as 
laminin, which has been shown to help axons regenerate3, and provide modality-specific 
tropic cues for sensory and motor axons, with a strong upregulation of neurotrophic 
factors in the distal nerve16,17,27. 
An important point to keep in mind is that in the PNS, the axons extend over vast 
distances, with the perikarya residing in or near the spinal cord.  Therefore only the axon 
proximal from the site of injury will remain connected to the neuronal cell body.  The 
distal part will undergo a process termed Wallerian degeneration in the case of 
transections injuries, or Wallerian-like degeneration in crush injuries25,26,28, under which 
the distal axons are cleared through an internal axonal breakdown followed by 
recruitment of immune cells29.  The breakdown of distal axons, infiltration of myeloid 
cells, and clearance of debris from the distal nerve is necessary for regeneration to 
proceed30-34.  
1.2 Challenges facing peripheral nerve repair and functional 
regeneration 
The rate of nerve regeneration has been found to be between 1-4 mm per day, 
correlating with the rate of slow axonal transport of important cytoskeletal proteins 
synthesized in the perikarya2,35.  The limited extension rate becomes a problem as the 
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chronically denervated distal nerve has a declining ability to support regeneration36.  
While there is a robust upregulation of trophic and tropic factors in the distal stump at 
first, this is not retained over long periods of time and the axons lose the attractive cues 
that promote their growth36,37.  Furthermore, while there is a strong angiogenic response 
in the acute phase5, chronically denervated nerve trunks become ischemic with a 
declining perfusion through the vasa nervorum37.  Guidance cues for axons are also lost 
through SC atrophy with an associated loss of Büngner bands and basal lamina tracts38-40. 
Chronically denervated muscle tissue also undergoes atrophy, and the number of 
spared muscle fibers is correlated with the number of innervating axons, showing a 
required nerve input for muscle tissue maintenance41.  The capability of motor endplates 
to be reinnervated also declines over time of denervation42.  Muscle atrophy has been 
reduced by engrafted embryonic motor neurons, or motor neurons derived from human 
pluripotent stem cells43-46.  A recent study showed that direct depolarization of muscle 
fibers using optogenetics reduced the muscle atrophy47, suggesting that the atrophy 
results at least in part from lack of depolarization and muscle contraction.  Ectopic 
innervation and long-term stimulation however seems to reduce receptivity to 
reinnervation in chronically denervated muscle48, suggesting that other interventions are 
needed to maintain motor endplates receptive of reinnervation, or to provide the 
regenerating axons with appropriate signals to efficiently innervate.  The limitations on 
axonal regrowth rate and declining support thereof coupled with end-organ atrophy make 
regeneration over long distances extremely challenging in the PNS, and a reasons why 
injuries more proximal to the CNS generally display poorer functional outcomes 
compared to more distal ones. 
 5 
Another challenge lies in the specificity of the regenerating axons, both in terms 
of discriminating between sensory and motor pathways, and to avoid innervating 
antagonizing muscles with the same motor neuron pool.  The control over motor vs. 
sensory specificity in reinnervation is thought to be controlled through the SCs.  In a 
process named preferential motor reinnervation (PMR), Brushart et al. observed that 
motor axons preferentially regenerate through motor tracts in a femoral nerve transection 
model, even if the sensory and motor branches were purposely misaligned49.  The process 
of correct motor nerve target innervation was improved over time, with collateral 
projections form the same motor neuron extending into both the motor and sensory 
branches having the incorrect collaterals removed, suggesting a pruning of incorrect 
innervation into sensory trunks50.  As PMR takes place even when access to the target 
end-organ is removed, the process appears inherent to the nerve trunk modality51.  
Furthermore, SCs have been shown to differ in their phenotype and injury response 
depending on their associated axons, secreting modality-specific tropic factors17,52,53.  
After spinal root avulsion, where no or very limited axonal contact is retained with 
supporting SCs, motor nerve grafts have been shown superior to sensory nerve grafts in 
promoting motor neuron survival54.  The modality specificity is thus not only important 
for path finding, but also for support of neuron survival.  These effects may be even more 
evident in the spinal root avulsion model where the injury is very proximal to the 
perikarya and there is very limited modality-specific SC support of the neurons retained.  
The ability of nerve trunks to support PMR has been found to decline with age55. 
In terms of target muscle innervation, a comparison between nerve transfers to 
direct repair is useful to understand the problems faced in repairing nerves with multiple 
 6 
antagonistic target muscles.  Intercostal nerve transfer is a procedure that may be 
employed in severe injuries to the brachial plexus, nerves innervating the hand and arm.  
Here the intercostal nerves, which control chest expansion for breathing but can be spared, 
are surgically transferred to innervate the target muscles of the brachial plexus.  In doing 
so, entire motor neuron pools are transferred to innervate and serve the same target 
muscle, and the brain can adapt to controlling the movement of its new pathway through 
central compensation.  The key here is that the entire motor neuron pool, i.e. collection of 
lower motor neurons receiving the same input signal, will serve one target muscle.  In the 
case of nerve repair however, motor units (individual motor neurons that innervate a 
group of muscle fibers and constitute subdivisions of the motor neuron pool) from 
different motor neuron pools may get mixed, resulting in the same input signal 
contracting antagonizing muscles and reducing or abolishing the movement function.  
This is an especially challenging aspect of nerve repair, as there does not seem to be any 
plasticity at this level able to rescue or re-learn mixed projections from a pool of lower 
motor neurons56. 
As in most tissue, the regenerative capacity of the PNS diminishes with advanced 
age.  This is due to a multifaceted reduction in the repair response, but current evidence 
suggests that factors in the end organ, distal nerve and immune response fall short rather 
than factors intrinsic to the regenerating neurons.  At least these factors dominate over 
those intrinsic to the neurons.  The extension velocities of young and old axons are the 
same, but axons growing through an old nerve appear to follow a less direct path, 
navigating around debris57.  The gene expression profiles of neurons before and after 
injury have also been found to be similar between young and old mice58.  On the other 
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hand, grafts from young into old animals lead to a more robust response both in terms of 
innervation, debris clearance58-60, and support of PMR55, arguing that mechanisms 
intrinsic to the young graft are at play in the enhanced regeneration.  What is clear is that 
SCs less efficiently undertake a repair phenotype with advancing age.  A key observation 
supporting this is the delay with which cJun, a transcription factor orchestrating the 
transdifferentiation into the repair SC phenotype8, becomes uppregulated58.  All other 
observations in terms of impeded debris clearance, upregulation of injury response 
markers, and reduced macrophage infiltration may be resulting from this, although no 
causal link has been directly shown and effects from other cells involved are not to be 
excluded.  The difference in the role of macrophages is an unresolved issue.  It is clear 
that debris clearance is less efficient in aged animals58-60.  This could be due to both a 
reduced recruitment and a reduced functionality of the macrophages in aged animals.  
The former could further be due to inefficient signaling either from cells recruiting them 
to the site, such as SCs, or intrinsic to the macrophages to respond to the signaling and 
migrate to the site.  The lab of Ahmet Höke reported a reduced in vitro phagocytosis by 
macrophages isolated from aged rats as compared to young animals59, pointing to a 
mechanism intrinsic to the macrophages’ functionality.  In the study by Painter et al., 
they could not rescue the impaired clearance seen in aged mice through heterochronic 
parabiosis with a young animal, from which they excluded macrophage-intrinsic 
mechanisms58.  However, the graft will still contain old cells that may be more inefficient 
at the recruitment of the young macrophages to the site.  By pharmacological blocking of 
macrophage activation it has been shown that a reduced activation and recruitment 
clearly affects the myelin clearance also in young animals60.  While a reduced recruitment 
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in old animals could not be resolve in the study by Scheib et al., there was a reduced 
RNA expression of several cytokines responsible for macrophage recruitment59.  
Inefficient macrophage recruitment could also extend to delayed revascularization of the 
graft22.  In conclusion, current evidence suggests that age-dependent decline in PNS 
regeneration is strongly associated with a declining capacity of the distal nerve to support 
regeneration, but that the neurons maintain a robust repair response.  It is however 
unresolved if the entire impairment is manifested in the distal nerve tissue, or if there is 
an immune cell-intrinsic component. 
Injuries of large portions of nerves become challenging to manage surgically.  Up 
to a certain size, the damaged tissue can be removed and direct nerve anastomosis 
performed between the nerve stumps.  If large portions of nerve tissue have to be 
removed, the ends cannot be brought together directly due to the tension in the tissue 
from doing so will contract blood vessels and restrict blood flow to the tissue.  In this 
case, a nerve graft or nerve transfer has to be employed61.  The current gold standard for 
very large defects is to use an autografts, where nerve tissue is taken from less critical 
places in the patient and engrafted to the site.  In doing so, the tissue already contains the 
nerve architecture with basal lamina tracts as well as support cells such as SCs, 
fibroblasts, endothelial cells and macrophages, which creates a graft vastly superior to 
any acellular graft.  There is however a limit to how much suitable tissue that can be 
spared, and there are also complications with morbidity at the donor site.  Much effort 
has thus been put forth to create good alternatives by using synthetic grafts or 
decellularized tissue62.  While acellular grafts over short distances can be repopulated by 
SCs migrating from the host tissue at the ends, studies in mice suggest that cellular 
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senescence eventually restricts the ability of host cells to repopulate the graft63.  It should 
be noted that it remains unclear if this mechanism translates to rat or human SCs.  In vitro, 
SCs from rats and humans have better expansion capabilities than those derived from 
mice64-66, but any direct comparison has not been made in terms of in vivo senescence.  
The performance of synthetic nerve guides can therefor be greatly enhanced by pre-
seeding them with support cells, ideally SCs due to their importance in orchestrating the 
regenerative response and remyelinate axons.  The availability of autologous SCs is 
restricted for the same reasons as for autografts.  This has created a need to identify 
alternative sources of SCs, such as through cellular programming from other cell 
types1,62,67. 
1.3 Contrast to the central nervous system 
The response to injuries is different between the PNS and CNS, as are the 
prospects for functional regeneration to take place.  This is not due to an inability of the 
CNS neurons to regenerate, but rather an effect of the tissue, immune cell and glial 
response to injury in the tissue.  Two seminal studies demonstrated this by showing that 
CNS neurons could extend robustly through PNS grafts in settings where axonal 
regeneration would normally not take place in the CNS68,69.  Engraftment of adult DRG 
neurons into the corpus callosum later demonstrated that when this was done successfully 
in a minimally invasive manner that did not elicit an injury response and upregulation of 
growth-inhibitory chondroitin sulfate proteoglycans (CSPGs), graft axons could extend 
along white matter tracts of the brain.  When the engraftment elicited a reactive response, 
the axons were halted at the graft/host interface70.  These studies demonstrate that the 
tissue response to injury differs significantly, in a way that for PNS tissue permits 
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regeneration while in the CNS a barrier is formed through which axons cannot extend 
under normal conditions.  This barrier is known as the glial scar, which serves to re-
establish the compromised blood-brain barrier.  The scarring has been shown necessary, 
as vast inhibition of scar formation increases the extent of tissue damage71-74.  It is 
comprised of a multitude of cell types that upregulate and deposit multiple extracellular 
matrix components inhibitory of axon extension.  We will not discuss the details of the 
scar formation in this dissertation, but there are some excellent recent reviews of the topic 
to be found75-78.  Instead we will focus on a couple marked differences in the injury 
response that may explain why CNS axons that fail to regenerate through injured CNS 
tissue may be able to extend through PNS grafts. 
First, there is a great difference in the response of the respective myelinating glia.  
While SCs associated with injured distal axons will actively clear the myelin, first by an 
autophagocytotic process and then by active myelin debris clearance and immune cell 
recruitment8-10,12,13, myelinating oligodendrocytes seem to serve no active role and 
frequently undergo apoptosis upon denervation after spinal cord injury79-81.  In the CNS, 
oligodendrocyte progenitor cells (OPCs) become activated to migrate towards the lesion 
site and produce both new OPCs as well as oligodendrocytes76,82-84.  Dystrophic axons 
have been found associated with NG2+ and vimentin+ cells at the penumbra of the lesion, 
the edge that is otherwise non-conductive of axonal growth.  Vimentin is expressed by 
multiple cell types, including OPCs, macrophages, ependymal cells and pericytes83, and 
NG2 is a cell-surface CSPG found on macrophages and OPCs85.  Thus, at least a subset 
of these cells seems to stabilize the dystrophic axons.  It remains unresolved which 
lineage these cells come from, but it has been proposed that axons may synapse onto 
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NG2+ cells, both stabilizing them but also preventing them from later axonal 
extension76,83. 
There is also a marked difference in how the CNS and PNS facilitate Wallerian 
degeneration, which is significantly slower in the CNS.  Upon PNS injury, the blood-
nerve barrier opens up distal to the site of injury to allow for efficient infiltration of 
immune cells and clearance of myelin debris in the distal nerve28,86.  The blood-brain 
barrier of the CNS however remains intact distal from the injury, maintaining the 
integrity necessary for neuronal survival but also limiting the ability to clear myelin 
associated with dystrophic axons by invading macrophages76.  It also prevents the 
opsonization of myelin debris by complement factors and antibodies from the blood, 
which has been shown as a key mediator of myelin phagocytosis by macrophages34,87-91. 
The PNS and CNS microenvironments also have a marked impact on the 
phenotype of macrophages and microglia.  Macrophages have been classified according 
to their activation state, from inactive M0 to the two activated phenotypes M1 and M2.  
Without going into detail regarding these phenotypes, the activation is mediated by 
distinct cytokines, where M1 is seen for instance upon IFN-γ exposure, rendering the 
cells to secrete pro-inflammatory cytokines, cytotoxic mediators such as reactive oxygen 
and nitrogen species, and increasing their phagocytic and antigen-presenting capacity.  
M2 polarization results from for instance IL-4 exposure, upon which M2 macrophages 
reduce their production of inflammatory cytokines.  In non-neural tissue the M2 
macrophages have been found important for dealing with extracellular pathogens77.  
Macrophage polarization is therefore controlled by the microenvironment in which they 
act, and studies pre-incubating macrophages with PNS tissue prior to engraftment into 
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spinal cord92 or optic nerve93 injuries led to enhanced regenerative outcomes.  However, 
as neither study used a non-stimulated control or macrophages stimulated by CNS tissue, 
but rather did non-cellular mock injections, a direct causal link by the stimulation could 
not be established.  It can be argued that improperly polarized macrophages will be 
detrimental to CNS cell survival, as secreted factors such as reactive oxygen and nitrogen 
species will cause secondary damage76,77.  Engrafted M2 polarized macrophages also 
mostly fail to retain their polarization over long periods in the CNS, arguing that the 
tissue promotes an M1 or non-polarized phenotype over an M2 phenotype94.  The site of 
a spinal cord injury is essentially deplete of IL4, delivery of which causes macrophages 
to undertake an M2 phenotype, with reduced tissue damage and enhanced recovery as a 
result95.  To summarize, the Wallerian degeneration is much more effective in the PNS 
than in the CNS, largely due to the response of the glial cells, where SCs of the PNS take 
upon an active role.  There is also an important contribution from tissue access from 
blood-derived macrophages and opsonins, as well as the local environment’s effect on the 
polarization contributing to a more rapid clearance of debris in the PNS.  While the 
myelin debris is cleared from the distal nerve of the PNS in 1-2 weeks96,97, myelin debris 
may persist for years after CNS axon degeneration in humans98-100. 
There are also structural differences between the CNS and the PNS that impact 
axonal regeneration and directional regeneration.  SCs form tracts of basal lamina, with a 
laminin-rich tube surrounding myelinating SCs.  After Wallerian degeneration, SCs will 
align within these tracts in bands of Büngner25,26.  As oligodendrocytes lack such basal 
lamina structures, they also lack these structural cues of directional guidance that also 
isolates the regenerating axons from exposure to inhibitory molecules.  The bands of 
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Büngner may contain cytokines assisting regeneration2, and laminin itself has been 
shown beneficial to axonal regeneration in the PNS3,101.   
The differences between CNS and PNS tissue regeneration is useful for finding 
interventions both for CNS and PNS regenerative therapies.  The obvious approach is to 
study the regenerative potential of the PNS, figure out what factors that are at play, and if 
these aspects can be used to promote CNS regeneration.  With this in mind, the classical 
engraftment models with PNS tissue interfacing the brain68,69 should be re-visited in light 
of current techniques and understanding of the microenvironment’s impact on immune 
cells and glia, looking more in-depth at how the PNS tissue may affect the border region 
from which neurons extend their axons into the graft.  A less obvious lesson is how 
aspects learned from CNS injury and disease can be used to promote PNS regeneration.  
In Chapter 4 of this dissertation, we demonstrate that a transdifferentiation of OPCs into 
SC-like cells seen in certain experimental demyelination models102-104 and in patients 
suffering from multiple sclerosis105,106 also could occur upon heterotopic engraftment of 
OPCs into the PNS, resulting in remyelination of regenerating axons by SC-like cells 
derived from the graft.  This type of fate specification due to environmental factors can 
also be leveraged for CNS applications in the classical way of providing more pro-
regenerative phenotypes in support cells.  Recent reports on axonal extension through 
glial scar where cytokine-laden hydrogels were employed in the model failed to consider 
the contribution these had on resident and recruited glia107,108.  The key to these findings 
may not be intrinsic to the regenerating neurons, but to the recruitment, phenotype and 
polarizations adapted by glia and macrophages respectively to support the regeneration. 
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1.4 Schwann cell development 
SCs develop from the neural crest stem cells (NCSCs), which is a transient cell 
population forming at and migrating out from the border between the neural plate and the 
newly fused neural tube in its most dorsal region.  They will give rise to a vast array of 
cell types, including melanocytes, cardiac cells, neurons and glia of the PNS.  The origin 
and migratory path of the cells will play an important role in their fate commitment, with 
the NCSCs that give rise to SCs arising from the trunk cells109 .  The specification of cells 
into NCSCs is induced by a combination of Wnt, BMP and FGF signaling that activates 
an intricate gene regulatory network110.  FGF signaling induces the expression of Hairy2 
(a Hes1 ortholog in Xenopus) to attenuate BMP signaling in the initial neural plate border 
gene upregulation111,112.  Wnt signaling then allows Pax3 and Zic1 to induce the 
expression of a series of neural crest specifiers113-117, while BMP signaling induces Id3 
expression to inhibit the activity of Hairy2 and allow neural crest specification to 
proceed111. The sequence of transcriptional regulation events initiated will eventually 
result in the upregulation of the core transcription factors Sox10 and FoxD3, the 
expression of which are maintained throughout the specification of SCs118,119, and marks 
the specification of NCSCs from the neural plate border.  
The newly specified NCSCs will now undergo an epithelial-to-mesenchymal 
transition to migrate away from the neural tube, followed by specification into their 
different cell types.  For the purpose of this dissertation, focus will be on the specification 
into SC precursors.  Following the specification of sensory neurons which reside in the 
developing dorsal root ganglia (DRGs), the cells that will be specified into SC precursors 
migrate through these structures and interact with peripheral axons110.  It still remains 
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unclear what triggers this specification, as the transcription factors known to regulate this 
process (Sox10, FoxD3, AP2α and Pax3) are also expressed in other NCSCs that do not 
give rise to SC precursors120.  Sox10 has been found to play a key role.  It upregulates the 
expression of the neuregulin receptor Erbb3, which controls not only specification but 
also makes the specifying SC precursors receptive to axonal support necessary for their 
survival121-128.  The level of Sox10 is controlled by a mechanism involving histone 
deacetylases HDAC1/2, where the Pax3 promoter is activated through interactions 
between Sox10 and HDAC1/2.  Pax3 then synergizes with Sox10 for enhanced levels of 
Sox10 expression associated with glial specification129.  While BMP signaling is 
inductive of neuronal fate130-133, this is suppressed by FGF2 and activation of notch 
signaling for glial fate commitment134,135.  Furthermore, maintained expression of the 
transcription factor FoxD3 is necessary for glial fate commitment over neuronal or 
melanocyte specification119,136. 
While the SC precursors are multipotent, giving rise to both mesenchymal stem 
cells, fibroblasts and parasympathetic neurons in addition to SCs, the next step in 
development into immature SCs is through to be irreversible.  The cells also switch from 
an axon dependence for their survival, to autocrine secretion of survival factors137.  The 
timing of AP2α downregulation in PNS development, along with in vitro results showing 
reduced differentiation of SC precursors into immature SCs when its expression is 
enforced, suggests that it is a negative regulator of the transition into immature SCs138.  
Notch signaling in SC precursors leads to downregulation of AP2α and an enhanced 
expression of the neuregulin receptor Erbb2, making the cells more responsive to 
neuregulin signaling and promotes proliferation of the cells139.  Once committed, the 
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immature SCs cease to migrate and associate with axons to undergo the process of radial 
sorting, where SCs take on a one-to-one relationship with axons to be myelinated, or 
embrace multiple small caliber axons into non-myelinated Remak bundles109. 
1.5 Cell reprogramming and engineering for regenerative medicine 
As already exemplified for PNS tissue in the discussion above, tissue regeneration 
does not take place for large injuries in most types of human tissue, liver being one 
exception.  To overcome the limited regenerative capacity, stem cell- and 
reprogramming-based approaches in tissue engineering and regenerative medicine rely on 
deriving human cells that can provide supportive cues to endogenous cells, and/or replace 
lost cell types, in order to regenerate tissue.  To achieve this, we need to produce the 
specified cell type from cells that can be obtained in a minimally invasive manner, and 
expand them to sufficient quantities.  Unless expandable progenitors can be isolated, this 
typically relies on reverting cells into a progenitor state, or propagating a different cell 
type that then can efficiently be converted directly into the target cell type. 
The cellular plasticity that enables these, often drastic, conversions of cellular 
identity has not been obvious.  Through studies of amphibian embryogenesis, it was 
believed that already in the late gastrula the cells began to be irreversibly committed to 
specific fates, and information required to generate other lineages was lost from the 
nuclei as the cells differentiated.  An at the time new technique called somatic cell 
nuclear transfer had enabled introduction of a cellular nucleus into an enucleated egg140.  
As nuclei from blastocysts could generate normal, healthy tadpoles, while those from the 
late gastrula were not able to do so more than infrequently, and it was never successful 
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beyond stages post-neurulae or later in the studies by Briggs and King, it was concluded 
that nuclei became differentiated and lost the information necessary to generate cell types 
beyond their specification141.  These views however became challenged by the results of 
a graduate student named John Gurdon in Michail Fischberg’s lab.  While the studies by 
Briggs and King were conducted in the amphibian Rana pipiens, Fischberg’s lab had 
switched to using the African frog Xenopus as they found benefits with their short time to 
reach sexual maturity, laboratory housing requirements, and ability to produce eggs all 
year around as opposed to the seasonal reproduction of Rana pipiens.  It turned out that, 
rather serendipitously, Xenopus was also better suited for successful somatic cell nuclear 
transfer from later-stage cell types142.  While most tadpoles were still abnormal, the 
finding that nuclei isolated from pre-hatching tadpoles143 or tadpole intestinal cells144 
could occasionally result in normal tadpoles and frogs supported the conclusion that even 
differentiated cells retain the information necessary to produce cells of all lineages of the 
adult animal; that the nucleus had not irreversibly lost any information, but that it was 
merely using select parts of it specific for the target cell.  This finding is the basis for all 
cellular reprogramming efforts thereafter, where manipulations can alter the gene 
expression profiles of cells to change their identity. 
A number of methods to make cells change their identity have since been 
explored. Access to human pluripotent stem cells, the progenitor of all cell types in the 
adult human body, was gained following their successful isolation from the inner cell 
mass of blastocysts145. These cells could be cultured in clusters called embryoid bodies 
that mimic their organization in embryonic development.  Through addition of specific 
growth factors, the cell fate can be directed by recapitulating the cues found in vivo. Such 
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techniques have been employed for instance in the generation of different neuronal cells 
from human pluripotent stem cells146-148.   
Another commonly utilized approach is to enforce the expression of the 
downstream transcription factors activated by these signaling pathways to direct cell 
specification.  The first demonstration of this however relied on two other seminal 
findings.  The first was that treatment of immortalized fibroblasts with 5-azacytidine, 
shown to incorporate into the DNA, resulted in transdifferentiation into chondrocytes, 
adipocytes and myocytes.  It was noted that time was required for the cells to undergo 
division149, and we today know that the incorporation of 5-azacytidine into DNA blocks 
DNA methylation by methyltransferases that act upon cell division, thereby changing the 
genes available for expression150. The other finding was that mature somatic cells also 
contained trans-acting factors that could induce gene expression of their lineage in the 
nuclei from other cell types.  This was done through fusion of two cells, in this case 
human amniocytes to mouse muscle cells, in a way that kept their respective nuclei 
separate and intact, upon which the human nucleus expressed genes related to the muscle 
cell151.  It was then possible to isolate the transcription factor responsible for inducing 
muscle cell gene expression in 5-azacytidine-treated fibroblasts.  Screening fibroblasts 
for myosin heavy chain expression after transfection with a myocyte cDNA library 
identified the factor MyoD, which was capable of converting immortalized fibroblasts 
into myoblasts similarly to what had previously been observed after 5-azacytidine 
treatment of the same type of cells152.  Many years later in 2006, a study identified a 
combination of four transcription factors that could convert mouse fibroblasts into so 
called induced pluripotent stem cells (iPS cells) by screening for combinations of 24 
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transcription factors known to be responsible for embryonic stem cell maintenance using 
lentiviruses to overexpress these constructs153.  The following year the same had been 
accomplished for human cells154-156, thus constituting a source of cells that can be 
produced in a minimally invasive manner, and produce all the cell types of the adult 
(even though this has not been strictly shown for human cells due to obvious restrictions 
to doing so in vivo).  Transcription factor overexpression is therefore a tool by which core 
gene regulatory networks can be induced using a part of the cells’ intrinsic gene 
regulatory machinery, bypassing extrinsic signaling cues that would normally determine 
its specification, and forcing the expression of fate-determining factors which are not 
present in the starting cell type.  This has been employed to directly convert fibroblasts 
into neurons157,158, and B cells into macrophages159,160, to name a few examples. 
Reprogramming techniques are now emerging as clinical therapies.  After 
encouraging results of maintained vision in rat models of age-related macular 
degeneration (AMD)161, retinal pigment epithelial (RPE) cells derived from human 
embryonic stem cells have shown promise in phase I and phase II clinical trials for the 
treatment of dry AMD and Stargardt’s macular dystrophy162,163.  While injection of cells 
in suspension gave integration into the host macula, the coverage was patchy163.  Efforts 
are now underway to develop cell culture scaffolds that allow for proper organization of 
the derived cells in culture, and to improve the coverage by providing a support matrix to 
facilitate the engraftment164,165.  Efforts like these to create better in vitro culture systems 
will be crucial to improve the quality of the cell preparations.  An example of where the 
quality and purity of the engrafted cells have shown to be important is for the treatment 
of Parkinson’s disease (PD).  In classical PD, A9 dopaminergic neurons of the substantia 
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nigra pars compacta are lost, interrupting the dopaminergic input from the nigrostriatal 
pathway to the dorsolateral striatum that regulates motor function166.  Clinical trials 
engrafting human fetal midbrain tissue provided evidence for the use of cell therapy to 
treat PD, but the results were varying between patients, with some showing significant 
improvement while others had no improvement and “troublesome dyskinesia in a 
significant proportion of patients after transplantation” was observed167.  This was likely 
due to the heterogeneous graft material, where the mDA neurons make up only a fraction 
of the cell population166,168. 
All but one of the clinical trials involving cells derived from pluripotent stem cells 
have used embryonic stem cells as their starting material, with only one patient in Japan 
receiving iPS cell-derived RPEs169.  While the first methods for deriving iPS cells relied 
on viral vectors for the transcription factor overexpression, non-viral170-172 and non-
integrating173 techniques have since been developed to overcome the risk of insertional 
mutagenesis and oncogene activation.  Nevertheless, there are concerns regarding the 
genomic stability of iPS cells.  The maintenance of site-specific methylation has been 
estimated to have fidelity of 90%-98%.  Thus, vast expansion of progenitor cells can and 
will lead to random and unpredictable changes in the DNA methylation which may affect 
their gene expression174-176, and clones with favorable gene expression patterns or 
chromosomal rearrangements get a growth advantage.  This can for instance be through a 
common partial gain of chromosome 12, which has been shown to increase their 
expression of Nanog and Gdf3177,178. The reprogrammed cells may also have erased their 
epigenetic marks more or less efficiently, leading to clones that carry a memory of their 
starting cell type179-181.  This leads to differences in the quality of iPS clones, and some 
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more or less biased to differentiate into certain lineages.  In order to robustly and 
reproducibly derive cells with a predictable functionality from different individuals, these 
challenges and shortcomings in reprogramming need to be overcome.  Extended culture 
has been shown to ameliorate some of the somatic cell memory seen in iPS clones, 
potentially due to incomplete reprogramming at early passages and continued selection 
for clones under culture conditions supporting pluripotency182-185, but it is also associated 
with the risk of accumulating mutations that may be detrimental or even dangerous.  
Some of the lineage bias between lines may be difficult to completely overcome, as data 
suggests that iPS cell heterogeneity is largely due to disparities between donors and not 
tissue of origin186,187.  A potential approach is to use in silico analysis of both gene 
expression, global DNA methylation and histone modification profiles to predict the 
differentiation potential of iPS clones185,188.  For clinical applications, both the effects 
from aberrant epigenetic profiles and mutations associated with the reprogramming 
process and cell expansion, as well as stable cell fate commitment need to be addressed to 
avoid transplantation of tumorigenic cells to the patients189,190. 
Finally, a major limitation with current cell programming and derivation methods 
is that they tend to produce immature progeny, rarely reaching cell phenotypes and 
mature functions seen beyond the perinatal stage191.  This is especially challenging for 
organ systems that continue to mature and develop well past birth, such as the nervous 
system.  Recent advances in organoid technology have however created methods to study 
prenatal development of a range of tissues through liver192, pancreas193,194, stomach195, 
and brain196 organoids to name a few examples.  This way, composite tissue from early 
development can be created in the lab, composed of the relevant cell types for that organ 
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system197,198.  Nutrient diffusion and waste transport however restricts their in vitro 
culture, as the construct is not perfused and eventually forms a necrotic core.  This limits 
the size and duration over which the organoid development may proceed198.  Even if 
endothelial cells were to form a vascularized construct, perfusion would not happen, as 
there is no heart.  This has created a biomedical engineering challenge to integrate the 
organoid with a system to perfuse it without perturbing the culture requirements allowing 
for the cells to self-organize, or to subdivide established organoids into sizes that are no 
longer diffusion-limited while retaining essential tissue organization.  There are 
occasions where composite cellular grafts will be beneficial, as exemplified by engrafted 
liver organoids that successfully integrated with the host vasculature192.   However as 
described above, fetal tissue-derived grafts have been limited in their applicability for the 
treatment of PD, likely due to their heterogeneity166-168.  In these cases organoids may 
serve as culture vehicles from which the desired cell population can later be isolated.  
Heterogeneity is not a problem only inherent to organoids.  Many derivation protocols 
also end up with a sizeable population of non-specific progeny, requiring purification 
steps to isolate the target cells199. 
In conclusion, cell programming techniques are widening our abilities to provide 
cell therapies for regenerative medicine where suitable cell sources cannot be directly 
isolated.  Some major challenges that remain include the robustness and specificity of the 
programming methods, and to derive functionally mature progeny past embryonic 
development. 
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1.6 Stem cells for peripheral nerve repair 
A vast number of different stem cell sources have been employed in experimental 
models of peripheral nerve repair.  They all however follow a hierarchy of support 
mechanisms, which is 1) extracellular matrix deposition and remodeling, 2) secretion of 
cytokines, exosomes, and neurotrophic factors that influence both regenerating axons and 
support cells, and finally 3) cells that can remyelinate the regenerating axons.  While 
pretty much any cell that can survive engraftment can be argued to act through the first 
two mechanisms to some extent, only very few cell types and sources have been shown 
capable of remyelinating the regenerating axons. 
While neural stem cells (NSCs) cannot be isolated in a non-invasive manner, they 
can be readily induced from pluripotent stem cells200-202, thus comprising a potential cell 
source for peripheral nerve repair.  A study conducted using a neural stem cell line found 
them capable of promoting regeneration in a rat chronic denervation model203.  4 month 
after engraftment, only about 0.5-1% of the engrafted NSCs were found to remain in the 
tissue, and they all were found positive for the neural stem cell marker nestin.  The main 
supportive effects must therefore have taken place at earlier phases.  In vitro analysis 
showed the cells to express MMP-2, suggesting that they can remodel the extracellular 
matrix.  Transfection of the cells to overexpress GDNF didn’t show any significant 
additional improvement.  In light of previous reports of these cells expressing large 
quantities of trophic factors204, the naïve cells may therefore have already had a robust 
trophic support rendering the GDNF transfection redundant.  The study also demonstrates 
that cell therapies may be an effective way to provide the trophic support lost in the distal 
nerve over prolonged denervation36,37. 
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Mesenchymal stem cells (MSCs) comprise a very commonly employed cell 
source.  They can be isolated from for instance blood, Wharton’s jelly of the umbilical 
cord, adipose tissue and bone marrow.  While cells from these different sources also 
differ in their differentiation potential and phenotypes, we group them together in the 
scope of this discussion1,205.  The cells are popular since the naïve cells have consistently 
been found safe in multiple clinical trials in various applications.  Furthermore they have 
displayed an immune-modulatory effect, reducing the inflammation, although others 
argue that the cells may rather be immune-privileged, not eliciting an immune response in 
the host themselves, and whether or not they provide a pro- or anti-inflammatory tissue 
response depends upon their prior conditioning1,205.  A common scientific malpractice is 
therefore to argue for the use of MSCs to act as beneficial immunomodulators without 
ever confirming that it holds true for the cell preparations used in the studies.  To further 
assume that they are non-immunogenic upon differentiation into other lineages is even 
less justified.  For instance, the immunogenicity of iPS cell-derived cells varies greatly 
depending on the cell fate they have assumed206.  The immune tolerance must therefore 
be evaluated specifically for every application and cell preparation method.  For 
peripheral nerve applications, MSCs are often differentiated into a SC-like phenotype.  
The first protocol was devised by Dezawa et al. in 2001207, after which over 100 reports 
employing such cells have been published205.  Through the differentiation the cells 
become more potent in promoting nerve regeneration in at least two ways.  First, they 
upregulate multiple neurotrophic factors which greatly improves their ability to support 
nerve regeneration over undifferentiated MSCs208.  Second, they have repeatedly been 
shown to be functional and myelinating207,209.  Nevertheless, studies comparing the action 
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of MSC-derived SCs to primary SCs have still found them to be less functional.  Axons 
in nerve guides loaded with MSC-derived SCs do not extend as efficiently as those in 
nerve guides loaded with primary SCs210, and ultrastructural analysis of their myelin has 
shown somewhat aberrant morphologies, especially when analyzed at later timepoints211.  
The phenotypic stability of the cells also depends upon signaling from neurons, as MSC-
derived SCs that have been co-cultured with DRG cells do not revert from their SC 
phenotype to the same extent as cells that have not been co-cultured with DRG cells212.  
These studies have all used murine MSCs in murine hosts.  For human MSC-derived SCs, 
there are so far no reports of functional myelination to the best of our knowledge, 
although there are studies that have derived SC-like cells from human MSCs213-215. 
Additionally, stem cells isolated from the skin216, termed skin-derived precursors 
(SKPs), have been shown to differentiate into SC-like cells217-219.  Their reports of a 
functional, myelinating phenotype however requires closer examination.  In the report by 
McKenzie et al.218 they show SKP-derived cells that are associated with axons and also 
label positive for Ki67, a cell proliferation marker.  This is by no means a myelinating 
cell, as SCs turn post-mitotic upon myelination,220,221 and perfect co-localization of MBP 
with the YFP reporter is unlikely.  Furthermore, after engrafting the cells distal to the site 
of a sciatic nerve crush injury in rats, the MBP staining overlapped nearly perfectly with 
the YFP reporter from the engrafted cells, but there was no MBP signal in nearby nerve 
tissue218.  Presumably, the site would have been littered with host SCs also engaging in 
myelination, so it is highly suspicious that no such signal was seen. A later report by the 
same lab showed no more convincing evidence217, and these results simply point to bad 
staining and imaging practice in the lab rendering these results inconclusive, even though 
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well-renown journals seem to give them a pass when it comes to overstating their results.  
They did report convincing evidence of myelination for human SKP-derived cells upon 
engraftment into the dysmyelinated Shiverer mouse brain.  A basal lamina structure could 
however not be discerned from the images presented, nor any other evidence that the 
cells retained a peripheral glia phenotype when engrafted into the brain218.  The 
phenotypic stability was evaluated by Walsh et al.219.  SKP-derived SCs were engrafted 
into decellularized sciatic nerve grafts.  10 weeks after engraftment, about 2/3 of the 
engrafted cells retained an S100β expression, a marker for mature SCs.  Their in vitro 
results also demonstrated myelination in a more convincing way than that discussed 
above. 
For human pluripotent stem cells, there are a few reports of SC-like cell 
derivations222,223, as well as some reports of direct differentiation from fibroblasts224,225, 
but they have shown limited if any functionality in terms of myelination.  Two studies 
indicate possible myelination in co-cultures with rat DRG neurons223 or human 
embryonic stem cell-derived NSCs225, but the neuronal cell preparations cannot be 
assumed to be 100% pure from myelinating glia, so the lack of reporters in the SCs 
together with the low observed frequencies of myelination (personal communication with 
the authors) raise the possibility that the MBP staining was due to contaminating glia. 
The overall lack of functionality obtained in human cell preparations can be due 
to a number of factors.  First the effect can be a result of suboptimal in vitro culture 
conditions.  The cells could differ in the media requirements from those commonly 
employed in mouse or rat SC myelination assays.  Second, it could be a species mismatch 
issue, with murine cells or hosts commonly employed both for in vitro and in vivo studies, 
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resulting in the potential failure of axon to SC communication hampering myelination. 
This may be overcome through the use of human cell-derived neurons, but then two 
additional questions arise: are the neurons of a mature phenotype that can be myelinated, 
and can co-culture conditions be found where both neurons and glia requirements are 
met?  We tried this with human iPS cell-derived motor neurons in collaboration with the 
Maragakis lab, but despite several culture conditions tested, none were able to maintain 
healthy cells over prolonged periods of time.  Third, it could be that the stem cell-derived 
SCs are of an immature, progenitor phenotype, not yet ready for myelination.  In the best-
case scenario, long periods of contact with axons under the right conditions may allow 
the cells to mature.  Alternatively the maturation could be enforced.  Finally, the 
expression of canonical SC markers is no guarantee that the cells have fully undertaken a 
SC phenotype.  Partial non-SC phenotypes may have been induced, and the cells may be 
dysregulated in a way that blocks full functionality.  Examples of this have been seen 
before, but it required gene expression profiling and comparison to profiles from multiple 
tissues to identify an aberrant gene regulatory network node that could be silenced226,227.  
Silencing approaches can however be undertaken in a high-throughput fashion screen of 
multiple targets without prior knowledge of the underlying gene regulatory network if a 
robust and efficient functional metric or marker is available.  For the reasons discussed 
above, such an assay is not obviously available for human SCs.  The closest would be the 
dysmyelinated Shiverer mouse brain, where graft-derived myelin could be easily 
distinguished, but for low frequency events it is cumbersome and the brain 
microenvironment may have unintended effects on the phenotype of the cells under study. 
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1.7 Hypothesis and overall objective 
The overall objective was to provide a source of functional, myelinating Schwann 
cells from an accessible source to support regeneration of peripheral nerve injuries.  We 
focused our work on human pluripotent stem cell-derived SC precursor-like cells, under 
the hypothesis that enabling these cells to reach functional maturation to remyelinate 
axons also would improve their ability to support peripheral nerve regeneration.  We 
approached this by the method of overexpressing transcription factors that were known to 
control the maturation and myelination function, targeting cell-intrinsic gene regulatory 
mechanisms for the cell functionalization.  We also aimed to provide tools for achieving 
transgene overexpression in the target cells using non-viral gene delivery vectors in order 
to provide more translatable means to promote the cell functionalization. 
With a lack of functional, myelinating glia for peripheral nerve cell therapies, we 
investigated if oligodendrocyte progenitor cells (OPCs), the progenitors of 
oligodendrocytes that form myelin in the CNS, could survive and be employed in the 
PNS.  With prior reports from focal CNS demyelination models showing this cell type 
capable of undertaking a SC-like fate102-104, we further characterized the cell fate 
commitment in the PNS microenvironment.  This is, to the best of our knowledge, the 
first investigation of OPCs and their functionality in a heterotopic engraftment into PNS 
tissue. 
1.8 Specific aims 
Specific Aim 1: Establish an efficient non-viral gene delivery method to achieve 
controllable transgene expression in stem cell-derived SCs 
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In the experiments presented in Chapter 2, we evaluated several non-viral 
transfection methods; both on human fetal tissue-derived SCs, as well as on human 
pluripotent stem cell-derived SCs.  There was a marked difference in the requirements for 
transfection between the cells evaluated.  We developed a linear 
poly(ethyleneimine)/DNA polyplex transfection protocol utilizing a DMSO shock to 
reach high transfection efficiencies in human immortalized SCs.  This however did not 
translate directly into the stem cell-derived SC precursor-like cells, where cytotoxic 
responses were seen in several batches of cells.  Screening of multiple poly(beta-amino 
ester)/DNA-based polyplexes did not improve cell health or survival.  Based upon 
previous studies identifying anti-viral responses to cytoplasmic DNA172,228-233, we 
synthesized mRNA with modifications to mask it from the host innate immune response, 
with improved transfection results and ability to perform serial transfections (two 
sequential tested) with maintained transfection efficiency.  Collectively, these results 
indicate that the cytotoxic response was not dominated by the polymer carrier used, but 
rather through an anti-viral response to the DNA, and that efficient non-viral transfection 
could be achieved in human pluripotent stem cell-derived SC-like cells through the use of 
modified mRNA polyplexes.   
Specific Aim 2: Determine the effects of key transcription factors on myelination 
using lentiviral constructs 
In Chapter 3, we present studies testing if overexpression of key transcription 
factors known to control the SC maturation and myelination process can enhance the 
myelination frequency.  We identified a transcription factor that directly increased the 
myelination frequency in primary rat SC/DRG neuron co-cultures.  Functionalization of 
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human stem cell-derived SCs with the same factor caused cell death.  Co-expression of 
the anti-apoptotic protein Bcl-xL alleviated this, although in only one batch tested so far, 
but the transcription factor overexpression failed to regulate known target genes despite 
robust transgene overexpression.  These results suggest that while such an overexpression 
has an effect in the context of primary SCs, the stem cell-derived cells do not have the 
underlying genetic regulation in place for the transcription factor to exert its function, at 
least not in the cell preparation tested. 
Specific Aim 3: Characterize the effects of cell functionalization on peripheral nerve 
injury regeneration 
In vivo experiments using functionalized primary SCs seeded into nerve guides 
are currently under way to determine if the in vitro results can translate into in vivo 
enhanced myelination frequencies in a sciatic nerve injury model in mice.  Nerve 
histomorphometrical evaluation will also be used to assess if it also may lead to an 
enhanced regenerative outcome, although the defect size possible in the immunodeficient 
mice may be too small to discern direct functional consequences. 
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CHAPTER 2 - NON-VIRAL GENE DELIVERY VECTORS 
FOR SCHWANN CELL TRANSFECTION 
2.1 Polyplexes and lipoplexes as DNA and RNA transfection carriers 
Plasmid DNA and mRNA constitute non-viral options with very low or no risk of 
stable genomic integration, respectively, thus alleviating clinical safety concerns from 
long-term transgene overexpression and insertional mutagenesis.  Naked or unprotected 
plasmids or mRNA molecules are however taken up by cells very inefficiently.  Both 
polyplexes and lipoplexes, that is carriers based upon cationic polymers and lipids 
respectively, enhance cellular uptake and transfection efficiencies by complexing with 
the DNA/mRNA1. 
For in vitro transfection and cellular entry, the plasmid or mRNA needs to pass 
several barriers.  First is to cross the cell membrane, which is rich in heparin sulfate 
proteoglycans and has a net negative charge, as do the polynucleotides1.  Lipid carriers 
typically consist of a neutral linker connecting a positively charged head group and a 
hydrophobic anchor2, while polymeric carriers have a positively charged backbone1.  The 
positive charge complexes with the negative charge of plasmid DNA or mRNA, 
abolishing repulsive charge effects and reducing its size that can be up to micrometer size 
for plasmids1, down to typically 150 – 600 nm for lipoplexes2 or 30 – 100 nm for 
polyplexes1.  In doing so, the complex acquires a net neutral or slightly positive surface 
charge that facilitates interaction with the cell membrane3.  Particles of this size may be 
taken up by endocytosis or macropinocytosis1,4,5.  Both plasmids and mRNA then need to 
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escape the endosome, liberate themselves from the carrier, and plasmids also need to 
enter the cell nucleus.  The exact order or mechanisms by which these steps occur are not 
well understood.  Lipoplexes are believed to fuse with the endosomal vesicle membrane, 
transferring the cargo through a flip-flop6.  Polyplexes, such as those based upon 
poly(ethyleneimine) (PEI), have been proposed to exit through the so called “proton 
sponge effect”7.  The theory is that the amines of the PEI buffer the acidic endosome, 
causing an influx of chlorine ions and an osmotic effect that causes the endosome to 
rupture.  The validity of this model is however questionable.  Theoretical calculations of 
endosomal membrane expansion from water influx appears insufficient to cause it to 
burst8, pH changes seem to be limited9, and imaging studies failed to observe any 
evidence of endosomal rupture10.  For the case of plasmids, they further need to make it 
into the nucleus to be transcribed.  Nuclear entry is greatly facilitated during cell division, 
as this is the only time that the nuclear membrane integrity becomes compromised.  
Otherwise molecules above 9 nm in size will have to go through an active transport via 
the nuclear pore complex1.  The localization of the endosomal release also plays a role.  
Release of plasmid DNA in the perinuclear space can increase transfection efficiency, as 
intracellular diffusion of plasmid DNA appears limited11-13. 
The chemical makeup of nanoparticles will impact both their uptake, trafficking 
and decomplexation patterns.  One of the most efficient polymeric transfection reagents 
is PEI, but it is also associated with cytotoxic response in cells14.  With all nanoparticle 
formulations remaining highly inefficient in trafficking, only a few percent able to escape 
endosomes4,10, the majority of the cargo that enters the cell fails to produce gene 
expression.  The rest may cause cytotoxic responses in the cells through a number of 
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mechanisms reviewed by Xue et al.14 and Parhamifar et al.15, including induction of 
reactive oxygen species by cationic materials, interactions with and disturbance of 
intracellular compartments, and a limited biodegradability.  As long as the intracellular 
trafficking and carrier release remains largely inefficient, carriers that exhibit efficient 
cellular entry will be correlated with the negative effects of doing so.  With very limited 
understanding of the process, we have but a few tools at our disposal to design carrier 
properties with predictable outcomes.  One such approach tackles both the toxic effects 
associated with polycations, and the disassembly of the carrier to liberate the cargo, 
namely design of degradable backbone moieties.  This can for instance be done by 
incorporation of disulfide bonds, leveraging the more reducing conditions upon cellular 
entry caused by the presence of cellular glutathione16-18. 
In addition to the cytotoxic effects from the carrier, the payload itself may cause 
antiviral responses compromising cell health.  Cytoplasmic presence of DNA19 or non-
self RNA20 is an indication of a potential viral infection, causing a cellular response 
ranging from release of signaling molecules to apoptosis21-23.  A number of mechanisms 
by which cells sense such DNA or RNA have been identified, as reviewed by Wu and 
Chen23.  While the Toll-like receptors (TLRs) that sense DNA or RNA in the endosomes 
are predominantly present in immune cells, TLR-independent cytoplasmic sensors act 
within the cytosol of somatic cells.  These sensors may distinguish between self and non-
self nucleic acids through foreign structures or motifs, or incorrect subcellular 
localization of the nucleic acids.  Consequently, transfection efficiencies can be improved 
by removal of such motifs, or by mimicking nucleoside and end modifications preventing 
immune recognition.  For instance, plasmid transfection efficiencies can be enhanced by 
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removal of the bacterial backbone components resulting in what are known as minicircle 
plasmids24,25, and mRNA transfection efficiency can be enhanced by removal of 5’ 
triphosphates26 and incorporation of modified nucleosides27-29.  Interestingly, two of the 
workhorses in in vitro transfection studies, the HEK 293T and HeLa cells, were found to 
lack an RNA polymerase III-independent pathway for sensing foreign DNA, and mouse 
embryonic fibroblasts lose this pathway after immortalization and serially passaging 
through yet unidentified mechanisms30.  This may in part explain differences in 
transfection efficiencies seen between immortalized cell lines and primary cells. 
2.2 Enhanced plasmid transfection efficiency in human immortalized 
Schwann cells by DMSO shock 
In order to develop efficient methods for plasmid transfection of SCs, we 
investigated if a brief exposure to a DMSO could improve transfection over that of the 
polyplex alone.  We used linear PEI with a number average molecular weight of 7 kDa, 
as PEI is a well characterized and broadly used polymer for transfection already 
employed in clinical trials31, and linear PEI with relatively low molecular weights have 
been shown to induce a less cytotoxic response than branched or high molecular weight 
counterparts14,15.  After a preliminary screen of DNA dose and DMSO exposure tolerance 
on human fetal tissue-derived SCs, DNA conditions with DMSO concentrations of 25% - 
30%, 1 – 2 min shock duration, 0.1 – 0.3 µg/cm2 of DNA, and a 4-hour incubation time 
prior to DMSO application were selected according to Table 1 for further investigation 
using a GFP expression vector. 
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Characterization of the fluorescence intensity of the transfected cells by flow 
cytometry 17 hours post-shock revealed a greatly enhanced transfection efficiency of the 
GFP expression vector when DMSO shock was applied (Figure 2-1).  Transfection 
without DMSO application was at a very low level (0.9% of cells, Figure 2-1E), while all 
groups subjected to DMSO treatment had >80% of the cells positive for GFP, giving 
almost an order of magnitude enhancement in yield of transfected cells. The highest 
transfection efficiency observed was 96.4 ± 2.0% (n = 12) of the cells under condition IV 
(Figure 2-1C, Table 2-1).   
The cell health was evaluated through a WST-1 metabolic activity assay, with an 
untreated control serving as the reference metabolic activity level.  Conditions I-III did 
not show a significantly reduced metabolic activity at 17 hours post-shock relative to the 
cells not receiving a DMSO treatment (Figure 2-1F), indicating that the cells maintained 
a good viability.  Condition IV, which also had the highest transfection efficiency, 
however displayed a significantly reduced metabolic activity relative to all conditions 
except III.  The general trend was for conditions displaying a higher average GFP 
intensity to also produce a reduced metabolic activity. 
Of note is that while all the DMSO-treated conditions had similar yield of 
transfected cells, the average fluorescence intensity was dependent on the transfection 
conditions.  Comparing conditions I vs. II shows an increased transgene expression level 
between DNA doses of 0.1 µg/cm2 and 0.3 µg/cm2 under otherwise identical conditions, 
indicating that a dose saturation point had not been reached at least for 0.1 µg/cm2 DNA 
dose.  As condition III, employing a lower DMSO concentration than condition II, 
showed a higher GFP expression level but lower (although not statistically significant) 
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metabolic activity suggests that the immortalized SCs tolerate the DMSO range used, and 
that toxicity may be more related to the transfection efficiencies produced.  This is in 
agreement with the trends observed across the groups compared.  Thus, the combined 
effects, not the mere exposure to DMSO or nanoparticles alone, dictate the impact on the 
cell health.  Similar observations were made when tested on human fibroblasts, but these 
cells much more sensitive to the cytotoxic effects of the transfection (Figure 2-2). 
To further study the applicability of the transfection method and observed 
transgene expression control, conditions I and III were selected for transfection of 
immortalized SCs with a pleiotrophin expression vector carrying a C-terminal GFP tag.  
These conditions using DMSO shock produced the biggest difference in transgene 
expression level, without significantly compromising cell viability (Figure 2-1E-F).  
Pleiotrophin (PTN) is a neurotrophic and neurotropic factor that exerts its function 
predominantly on motor neurons32.  Functionalization of SCs to secrete PTN may 
therefore be a strategy to promote and guide motor axon regeneration.  Secreted PTN in 
media conditioned over transfected SCs between 24 – 48 hours post-transfection was 
analyzed by dot blot, yielding 1.8 ± 0.1 ng/µl under condition I, and 2.7 ± 0.2 ng/µl under 
condition III, displaying a significant difference in expression level and confirming the 
previously observed control over transgene expression level (Figures 2-3 and 2-4).  
Analysis of conditioned media by fluorometry confirmed that the transgene expression 
level could be controlled by tuning the transfection conditions (Figure 2-5). 
Collectively, these results show that DMSO shock can enhance transfection 
efficiencies of PEI/DNA polyplexes, and that tuning transfection conditions also affect 
transgene expression levels.  This was observed for both human immortalized SCs, as 
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well as primary human fibroblasts, although the latter showed a greater sensitivity to 
transfection.  While it has previously been reported that DMSO shock can enhance 
transfection efficiencies for other cationic carriers, such as DAEA-dextran33, 
polybrene34,35, calcium phosphate36, and poly(L-ornithine)37,38, none have reported 
transfection efficiencies as high as those we observed employing DMSO shock with 
PEI/DNA polyplexes.  As they all used different cell lines for their studies, direct 
comparisons cannot be made due to cell type dependence.  We can however conclude 
that DMSO shock works very well in significantly enhancing DNA transfection 
efficiencies for PEI/DNA polyplexes.  None of the studies, ours included, can identify 
which step in the plasmid trafficking to the nucleus that is enhanced.  A likely candidate 
is the endosomal escape, based upon the fact that this step has been seen as highly 
inefficient in imaging studies4,10, and that direct passage through the cell membrane may 
not effectively bring the particles to the perinuclear space for subsequent nuclear entry11-
13.  It should however be noted that observation from lipoplexes suggest that DNA 
labeling can affect binding and decomplexation from the carrier, and therefore studies 
using labeled particles may not fully recapitulate the trafficking of non-labeled particles 
and plasmids39. 
The cell-type dependence on transfection efficiency can have several explanations, 
including different uptake mechanisms, mitotic activity, and transcriptional and 
translational activity.  Of note was however the sensitivity to transfection between 
immortalized SCs and primary fibroblasts used in our experiments, where immortalized 
SCs appeared much more tolerant than the fibroblasts.  While sensitivity to the nanotoxic 
effects discussed in the previous section could vary, an interesting thought is that they 
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may have different levels of sensitivity and response to cytoplasmic DNA.  As mentioned 
previously, Chiu et al. found that mouse embryonic fibroblasts lost the ability to detect 
foreign DNA through the RNA polymerase III-dependent pathway upon immortalization 
and serial passaging30.  It is therefore possible that such effects could have rendered the 
immortalized SCs more amenable to transfection. 
2.3 Transfection of human pluripotent stem cell-derived Schwann cell 
precursors 
Plasmid transfection conditions were screened for human pluripotent stem cell-
derived SC precursor-like cells derived in the lab of Dr. Gabsang Lee.  Transfection with 
plasmid DNA/PEI polyplexes and DMSO shock never produced conditions with 
reproducible results regarding cell survival and health, frequently wiping out entire wells 
of cells (data not shown).  Due to the high cytotoxicity observed, we screened a library of 
poly(β-amino esters)40 (PBEAs) to find carrier chemistries that may overcome the 
cytotoxic response.  While no DMSO was necessary to achieve good transfection 
efficiencies (Figures 2-6 and 2-7), the cells transfected displayed unhealthy morphologies 
at two days post transfection, which escalated as the dose was increased from 300 ng to 
600 ng in a 96 well plate format.  Figure 7 shows the best performing group for 
transfection yield while maintaining a relatively healthy morphology.  The transfections 
were however not compatible with serial transfections (data not shown), and the 
significantly reduced cell health with increased dose to 600 ng and only 40% transfection 
efficiency at 300 ng would render very low co-transfection efficiencies of multiple 
transcription factors at doses tolerable by the cells. 
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With such a wide range of carrier chemistries failing to alleviate the cytotoxic 
response, we asked whether or not it may be due to an antiviral response to the foreign 
DNA introduced rather than to the polymer carrier itself.  It has previously been reported 
that masking the mRNA from innate immune responses by nucleoside modifications has 
facilitated cell reprogramming41.  The modified mRNA transfection of GFP allowed for 
serial transfection using either PEI or PBEAs containing reducible di-sulfide bonds in 
their backbones as carriers, with dose-dependent transfection efficiency in SC precursor-
like cells.  A control transfection using PEI and DMSO shock did not display the same 
dose response nor any increase in transfection yield upon serial transfection (Figures 2-8 
and 2-9).  The cells also appeared overall healthier after transfection with modified 
mRNA than plasmid (data not shown).  These results suggest that the cytotoxic response 
and limited transfection capability of hESC-derived SCPs was due to, at least in large 
part, an anti-viral response to cytoplasmic DNA.  We do note that the results should be 
verified on multiple batches of stem cell-derived cells.  However, as the same batch of 
cells had a detrimental response to plasmid transfection, but retained a healthy 
morphology and growth after mRNA transfection, we believe that it is a likely 
explanation for our previous observations as well, and due to cost and time constraints 
moved the focus of our experiments to determining a combination of transcription factors 
that can functionalize the cells into a myelinating phenotype (see next chapter), intending 





Figure 2-1 DMSO shock enhances transfection efficiency of PEI/DNA nanoparticles in human 
immortalized SCs. 
Images of transfected Schwann cells under conditions IV (A, B) and I (C,D), conditions in Table 2-1.  GFP 
signal in green with nucleus (DAPI) in blue (A, C).  GFP signal depicted in black on white background (B, 
D).  Scale bar = 100 µm.  Bar graphs of average GFP expression level on left scale and % positive cells on 
right scale (E).  Average expression level was significantly different between all groups (p < 0.01, n=12, 
Ryan-Einot-Gabriel-Welsch test).  Metabolic activity relative to untreated control with homogenous subsets 




Figure 2-2 DMSO shock enhances transfection efficiency of PEI/DNA nanoparticles in human 
primary fibroblasts.  
Images of transfected fibroblasts under conditions V (A, B) and IV (C,D), conditions in Table 2-2.  GFP 
signal in green with nucleus (DAPI) in blue (A, C).  GFP signal depicted in black on white background (B, 
D).  Scale bar = 100 µm.  Bar graphs of average GFP expression level on left scale and % positive cells on 
right scale (E).  Average expression level was significantly different between all groups but III and IV, 
marked n.s. (p < 0.01, n = 10, Ryan-Einot-Gabriel-Welsch test).  Metabolic activity relative to untreated 






Figure 2-3 Tunable transgene expression level of PTN in supernatant of transfected human 
immortalized SCs. 
PTN levels in supernatant conditioned by immortalized Schwann cells 24 – 48 hours post-transfection 
under conditions I and III (Table 2-1) with a PTN expression plasmid.  Dot blot quantification PTN 
confirmed the controllable expression level (A).  Quantification relative to a standard dilution series of 
human recombinant PTN yielded 1.8 ± 0.1 ng/µl under condition I, and 2.7 ± 0.2 ng/µl under condition III, 
displaying a significant difference in expression level (B, concentrations of 10 ng/µl – 1.3 ng/ µl used for 
regression, lower dot of 1.3 ng/ µl excluded, R2 = 0.989, p = 0.02, Student’s independent two-tailed t-test, n 
= 3). Error bars = one standard deviation. 
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Figure 2-4 PTN dot blot standard curve. 





Figure 2-5 Controllable expression level of PTN as determined by fluorometry. 
PTN level in supernatant of transfected human immortalized SCs under conditions I (n=3) and III (n=4) 
according to talbe 2-1.  Values are normalized to that of the highest average expression.  The difference 




Figure 2-6 Screening of PBAE carriers for plasmid transfection of human pluripotent stem cell-
derived SCP-like cells. 
(A) Percent transfected as determined by flow cytometry.  (B) GFP expression intensity (FL-1 channel) 
above that of non-transfected cells.  Carrier names as described in Materials and Methods.  n = 4 per gourp.  




Figure 2-7 PBAE/plasmid polyplex transfection is limited by cytotoxic effects in human pluripotent 
stem cell-derived SCP-like cells. 
Human embryonic stem cell-derived Schwann cell precursor-like cells transfected with PBEA 537 and GFP 
expression plasmid at 300 ng (left) or 600 ng (right) DNA per well in a 96 well plate format, imaged at two 
days after transfection.  Images represent the best performing group of PBEA carriers tested.  Top row 
shows bright field image with GFP overlayed, and bottom shows GFP signal only in white on a black 




Figure 2-8 Modified mRNA transfection produces efficient serial transfections with a good dose-
response compared to plasmid transfection with DMSO shock. 
hESC-derived SCPs were transfected with either mRNA (A-H) or plasmid (G-I) at day 0 (open dots) or day 
0 and 1 (solid dots). (A-C) PBAE R646 carrier with (A) 100 ng, (B)150 ng or (C) 200 ng of EGFP mRNA 
(D-F) L-PEI 17kDa carrier with (D) 50 ng (E) 100 ng or (F) 150 ng of EGFP mRNA (G-H) L-PEI 7kDa 
carrier using DMSO shock at (G) 50 ng (H) 100 ng or (I) 150 ng EGFP plasmid under CMV promoter. 




Figure 2-9 Transfection yield of complete data set for screening of mRNA transfection carriers on 
hESC-derived SCPs. 
Carrier annotations as described in Materials and Methods.  n = 4 per group and time point. Error bars = 





Table 2-1 Schwann cell transfection conditions. 




Table 2-2 Fibroblast transfection conditions. 






2.6 Materials and Methods 
2.6.1 Plasmids and nanoparticle formation 
gWiz-GFP plasmid was purchased from Aldevron (Fargo, ND, USA). Plasmid for 
GFP-Myc-His-tagged human pleiotrophin (PTN) was produced by cloning cDNA for 
human PTN into pCDNA 3.1.  The nanoparticles were formed from a 100 µg/ml solution 
of plasmid DNA in water, to which an equal volume of linear PEI, MW = 7,000 kDa 
(Polymer Chemistry Innovations, Inc., Tucson, AZ, USA), as confirmed by gel 
permeation chromatography, was added by vigorous pipetting to achieve an N/P ratio of 
6. 
2.6.2 Human fetal tissue-derived immortalized Schwann cells: origin, 
culture and transfection protocol 
The immortalization and characterization of human fetal tissue-derived Schwann 
cells has been described elsewhere42.  The cells were maintained at 37oC, 5% CO2 in air, 
in a medium consisting of 10% (v/v) FBS (Gibco, Grand Island, NY, USA), 2% (w/v) D-
(+)-glucose (Sigma-Aldrich, St. Louis, MO, USA), 0.5 mM GlutaMAX™ (Gibco), 1X B-
27 Supplement (Gibco), 100 U/ml penicillin and 100 µg/ml streptomycin (Quality 
Biological, Gaithersburg, MD, USA) in 1X Neurobasal medium (Gibco).  Cells were 
passaged to an expansion ratio of 1 to 6 using TrypLE™ Express (Gibco) when reaching 
approximately 90% confluence. 
Cells were plated at ~10,000 – 12,500 live cells/cm2 as determined by trypan blue 
exclusion (Invitrogen, Grand Island, NY, USA) and Countess cell counter (Invitrogen) at 
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default settings. Transfection was performed the next day at approximately 30% 
confluence.  Prior to the DMSO shock, Schwann cells were incubated with DNA 
nanoparticles for 4 hours at 37oC, 5% CO2.  The shock was performed by aspirating the 
cell culture media, completely covering the cells with a solution of DMSO (ACS grade, 
Sigma-Aldrich) in DMEM (Mediatech, Manassas, VA, USA), aspiration, followed by a 
wash using DMEM before applying the cell culture medium. 
Varying concentrations of DMSO, DNA density and shock duration were used 
according to Table 1.  The shock duration was defined as the time from the application of 
DMSO solution until the cells received DMEM in the washing step. 
2.6.3 Fibroblasts:  origin, culture and transfection protocol 
Human neonatal dermal fibroblasts isolated from foreskin (American Type 
Culture Collection, Manassas, VA, USA, catalog number PCS-201-010) were maintained 
in DMEM with 4.5 g/l glucose, L-glutamine and sodium pyruvate (Mediatech) 
supplemented with 15% (v/v) fetal bovine serum (Gibco) and fibroblast growth factor 2 
(Peprotech, Rocy Hill, NJ, USA), using a 1 to 6 expansion ratio when cells reached near-
confluence.  At day 12 in culture, cells were plated at a density of 20 000 live cells/cm2, 
as determined by trypan blue exclusion (Invitrogen) and Countess cell counter 
(Invitrogen) at default settings.  Transfection was carried out the following day. 
The transfection was performed as described for the Schwann cells.  DNA and 
DMSO concentrations were varied according to Table 2-2. 
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2.6.4 Transfection efficiency and cell viability assessment 
17 hours post shock, Schwann cells for gene expression quantification were 
detached by TrypLE™ Express (Gibco), and an equal volume of neutral buffered 10% 
formalin solution (Sigma-Aldrich) was added to fix the cells.  The GFP transfection 
efficiency and average fluorescence intensity was determined by flow cytometry using a 
FACSCalibur flow cytometer and CellQuest Pro software (Becton Dickinson, Heidelberg, 
Germany) at an excitation wavelength of 488 nm and an emission wavelength of 530 nm 
(FL-1).  Signal amplification voltages were adjusted before each set of measurements not 
to saturate the scale for the brightest group, with absolute values reported in the graphs.  
Positive cells were defined as those with an expression level above which <0.01% of the 
control cells were found.  Comparisons were made between cells of the same passage that 
were transfected and analyzed in the same session to minimize methodological errors. 
Cells for fluorescent imaging were fixed for 20 minutes using 10% neutral 
buffered formalin (Sigma-Aldrich) and stained with 4',6-diamidino-2-phenylindole 
(DAPI, Invitrogen) for 10 minutes, with three washes in PBS after each step.  Cells were 
imaged with a Nikon Eclipse TE2000-E inverted microscope using Nikon CFI Plan Fluor 
10x and 20x objectives with N.A. of 0.30 and 0.45 respectively, as well as NIS Elements 
software (Nikon Instruments Inc., Melville, NY, USA).  Contrast was equally adjusted 
for all images with reference to a non-treated sample to eliminate autofluorescence.  
Black and white images were obtained by displaying the GFP signal in white using NIS 
elements, followed by a color inversion using Photoshop CS4 (Adobe Systems Inc., San 
Jose, CA, USA).  This was done to better visualize cells displaying a low expression level. 
 88 
Metabolic activity was assessed by a WST-1 assay (Roche Applied Science, 
Indianapolis, IN, USA) as an indication of the cell viability.  Assay was performed 
according to the manufacturer’s instructions, with volumes adjusted for 48-well plates.  
The absorbance at 450 nm was measured after 1 hour using a Tecan NanoQuant Infinite 
M200 plate reader (Tecan Group Ltd, Männedorf, Switzerland).  Metabolic activity was 
depicted as normalized to the value obtained for the untreated control.  Fibroblasts were 
analyzed the same way 24 hours post-shock. 
2.6.5 Pleiotrophin expression level analysis 
The transgene expression level of pleiotrophin was assessed by two assays. First, 
PTN concentration in the supernatant from transfected SCs was assessed via the GFP 
fusion tag.  For these experiments, the medium was prepared out of phenol red-free 
Neurobasal medium (Gibco).  The medium was exchanged 24 hours post-transfection, 
and subsequently collected for analysis 24 hours later.  Measurements were performed 
using a FluoroLog 3-22 fluorometer (HORIBA Jobin Yvon Inc., Edison, NJ, USA) with 
samples in plastic cuvettes.  Emission intensity of the supernatant from cells transfected 
under conditions I and III (Table 1) was collected from 495–700 nm with a 5 nm slit size, 
using a 480±5 nm excitation wavelength.  Comparison between conditions was 
performed on the peak emission value after smoothing using a lo-pass FFT-filter with a 
0.1 (nm)-1 cutoff, and subtraction of the emission from the supernatant of non-transfected 
cells using Origin 8 (OriginLab, Northampton, MA, USA). 
For a quantification of the secreted amount of PTN, cells were treated as for the 
above fluorometer assay, but first using regular Neurobasal medium (Gibco) followed by 
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OptiMEM® (Gibco) 24 hours post-transfection.  24 hours later, the supernatant was 
collected, a protease inhibitor cocktail (Sigma-Aldrich) was added and samples stored at  
-20oC until the time of analysis.  A standard dilution series was made from recombinant 
human PTN expressed in E.Coli (Sigma-Aldrich).  The lyophilized powder was 
reconstituted in PBS with added protease inhibitor cocktail (Sigma-Aldrich) and the stock 
concentration was verified by BCA protein assay (Pierce, Rockford, IL, USA) according 
to manufacturer’s protocol with a BSA reference performed in triplicate.  The stock was 
then diluted to concentrations of 10 ng/µl, 5 ng/µl, 2.5 ng/µl, 1.3 ng/µl and 0.6 ng/ µl plus 
blank. 
The dot blot was performed using 1 µl of sample per dot onto a nitrocellulose 
membrane (BioRad, Hercules, CA, USA), applied in two drops.  Blocking was performed 
over night at 4oC in 5% non-fat milk in TBST (BioRad).  Membranes were then 
incubated with anti-pleiotrophin (Sigma-Aldrich, P3743) at 0.5 µg/ml in 5% non-fat milk 
in TBST at room temperature for 1 hour, washed five times in TBST, reacted with HRP-
conjugated donkey anti-goat IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA, SC-
2020) for 2 hours at 0.4 µg/ml in 5% non-fat milk in TBST at room temperature for 1 
hour, followed by five washes in TBST at room temperature.  Development was done 
using Amersham ECL Prime Western Blotting Detection Reagent and an enhanced 
chemiluminescence ECL Western Blotting Analysis System (GE Healthcare/Amersham 
Biosciences, Piscataway, NJ, USA). 
The dot blot intensity was analyzed using ImageJ 1.46r (NIH, Bethesda, MD, 
USA) by first subtracting the background followed by intensity analysis of circular 
regions of interest centered at the dot with the area kept constant.  Using the standard 
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titration curve, the stain intensity was used to estimate the secreted concentration of PTN 
in the supernatant. The standard concentrations of 10 ng/µl, 5 ng/µl, 2.5 ng/µl and 1.3 
ng/µl (R2 = 0.989) were used, while 0.6 ng/µl was excluded as it was outside the linear 
range with the relevant exposure time, and the lower dot at 1.3 ng/ µl was excluded due to 
a mark on membrane (Figure 2A). 
2.6.6 Transfection of human embryonic stem cell-derived Schwann cell 
precursor-like cells 
Schwann cell precursor-like cells were derived from human embryonic stem cells 
in the lab of Dr. Gabsang Lee (Johns Hopkins University) according to a yet unpublished 
proprietary protocol.  The cells were provided as pre-seeded plates with media aliquots 
for use with the transfection. 
In vitro transcription (IVT) was performed as described by Warren et al.41 with 
slight modifications.  990 ng plasmid template was used for every 20 µl reaction, and 5’ 
capping was performed enzymatically using a ScriptCap m7G capping reaction 
(CellScript, Madison, WI, USA) according to the manufacturer’s instructions after the 
DNAse treatment, as opposed to inclusion of an ARCA cap analog in the IVT reaction as 
done by Warren et al.  The product was purified on MEGAclear columns (ThermoFisher, 
Waltham, MA, USA), eluted into nuclease-free water and the concentration adjusted to 
100 ng/µl and stored as single use aliquots at -80oC. 
PBAEs were synthesized and named as previously described for plasmids43 and 
RNA44.  For the plasmid transfection PBAE synthesis, ratios of backbone and side chain 
monomers are indicated (Figure 2-6).  For instance, “447, 1.1:1, 30 w/w, 600 ng” 
 91 
indicates that backbone monomer 4, side chain monomer 4, and end group molecule 7 
were used in the synthesis, with backbone to side chain monomer ratios at 1.1:1.  The 
mass ratio between carriers to DNA was 30, and the total dose in the well 600 ng.  For 
mRNA transfection, PBAEs were mixed with mRNA at a 1:1 mass ratio, while PEI was 
indicated by a nitrogen to phosphate molar ratio (N/P ratio) between carrier and mRNA.  
PBAEs have the final concentration in the media as indicated, as well as the total dose 
(Figure 2-9).  
2.6.7 Statistical analysis 
Statistical analysis was performed using SPSS Statistics 19 (IBM, Armonk, NY, 
USA). gWiz-GFP expression and metabolic activity was compared using MANOVA, 
Pillai’s trace.  Significant differences were followed up by ANOVA and Ryan-Einot-
Gabriel-Welsch or Games-Howell post-hoc tests when applicable, for groups with or 
without equal variance assumed respectively.  Equal variance was assessed by Levene’s  
test.  All tests were performed at a level of α = 0.05.  n = 12 samples per group for SCs, 
and n = 10 for fibroblasts. 
The PTN concentrations in the supernatant from the dot blot assay were subjected 
to two-sided independent t-tests with equal variance assumed following Levene’s test, 
both at a level of α = 0.05 (n=3). 
PTN expression in GFP-tagged fluorometer assay was compared by measured 
peak fluorescence intensity from the fluorometer readout, subjected to a one-sided 
independent t-test (α = 0.0005) (n=3 for condition I and n=4 for condition III, according 
to Table 1).  Equality of variance was determined by Levene’s test (α = 0.05). 
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CHAPTER 3 - HARNESSING THE TRANSCRIPTIONAL 
REGULATION OF SCHWANN CELL MYELINATION FOR 
IMPROVING CELL FUNCTIONALITY 
3.1 Introduction 
The transcriptional regulation underlying Schwann cell (SC) maturation and 
myelination is still an active research area.  A few key regulators have emerged that have 
served as candidate factors in our studies.  As outlined in Chapter 1, SCs arise from the 
neural crest precursor cells.  After maturation to the immature SC stage, the cells make a 
decision on whether to mature into myelinating or non-myelinating SCs.  The 
myelinating SCs, which are the focus of this dissertation, go through a so-called radial 
sorting process to form a one-to-one relation with their axons (as opposed to 
oligodendrocytes in the central nervous system that myelinate multiple axons, or the non-
myelinating SCs that support multiple small caliber axons without forming myelin), and 
take on a pro-myelin SC phenotype.  These cells then proceed to wrap around the axon, 
forming a dense, multi-layered membrane structure from which most of the cytosol is 
extruded1.  The myelin has a distinct makeup from the non-myelinating, activated, or 
immature SC membrane, and a feed-forward cascade of transcription factors drives the 
expression of the proteins that create and stabilize the myelin.  So far, three of the 
transcription factors that directly bind to regulatory elements of myelin genes for their 
activation and expression under normal development have been identified, namely Sox10, 
Oct6 (also known as Pou3f1, Tst1, or Scip), and Egr2 (also known as Krox20)2. 
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Sox10 is expressed throughout the different stages of SC development, starting at 
the migratory neural crest cell stage3, and is required for SC specification.  In SCs, it 
controls the expression of the neuregulin receptor Erbb3, important for SC migration, 
interplay between SCs and axons, and SC survival4-11.  Sox10 also takes part in the 
upregulation of Oct6 through homodimeric binding to the SC enhancer (SCE)12,13, 
constituting the first step of the feed-forward regulation, taking place at the pro-
myelinating SC stage14-16. 
In the next step, Sox10 and Oct6 upregulate Egr2 expression by acting upon a cis-
regulatory element called the myelinating SC element (MSE)17-19.  Mouse models 
deficient in Oct6 show a transient arrest at the pro-myelinating stage, but this is rescued 
through Brn2 expression, and myelination proceeds normally with a slight delay.  Double 
mutants for Oct6 and Brn2 however have their SCs terminally arrested at the pro-
myelinating stage, leading to hypomyelination20.  
For the formation of mature myelin to occur, Oct6 needs to be downregulated21, at 
least in part, by Egr222.  Sox10 and Egr2 continue to be expressed in the mature, 
myelinating SC, and are required for myelin maintenance23,24. 
While these factors constitute the known key orchestrators of SC myelination in 
the sense that they directly bind to the regulatory elements, they do not act alone.  Sox10 
has been found to recruit the BAF remodeling complex25 and HDAC1/226 in its 
regulation of the feed-forward cascade, and thus chromatin remodeling is likely required 
for the induction of Oct6 and Egr2.  Studies of CnB1 mutant mice, lacking a key subunit 
for calcineurin signaling, revealed a critical link between intracellular calcium signaling 
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induced through neuregulin signaling, and the upregulation of Egr2 and myelin protein 
zero expression through synergistic regulation by Sox10 and Nfatc4.  Thus, axonal 
signaling leads to dephosphorylation and nuclear entry of Nfatc4, resulting in myelin 
gene expression through cooperation between Nfatc4 and Sox1027 at the pro-myelinating 
SC stage.  Yy1 has also been shown to be a critical link in Egr2 induction, and in vitro 
studies suggest that neuregulin signaling activates Yy1 through posttranslational 
modification by MEK kinase activity to upregulate Egr2 expression28.  Additionally, the 
NuRD complex has been shown to be required for formation of myelinating SCs.  In 
animals with a conditional deletion of one of the key components of the NuRD complex, 
Chd4, hypomyelination and radial sorting defects and a misexpression of genes related to 
an immature SC phenotype late in development (P30) was observed.  The NuRD 
complex was found to be recruited to many of the Egr2 target sites, thus suggesting a 
recruitment of NuRD by Egr229.  Egr2 further depends on its interactions with Nab1/2.  
Mice lacking both factors phenocopy the Egr2 deficient mice30.  As the Nab proteins 
have been found to interact with Chd431 as well as Egr232, they have been proposed as a 
link for NuRD recruitment by Egr2 to regulatory sites, and can act as both co-activators33 
and co-repressors29,32.  Sox10 also depends on the Mediator complex in its activation of 
Egr2 expression.  Conditional knockout of the subunit Med12 in glia prevented 
myelination in both the PNS and the CNS.  For SCs, Med12 was found to be recruited to 
the MSE, and Sox10-induced activation of an Egr2 reporter construct was dependent on 
Mediator complex subunits for its activation, suggesting that Mediator complex 
recruitment by Sox10 to the MSE is required for myelin gene induction34.  It is of interest 
to note the importance of Sox10 in the specification and maturation of both SCs and 
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oligodendrocytes.  As in SCs, Sox10 plays a key role for cell specification as well as for 
terminal functional differentiation into myelinating oligodendrocytes, but the target genes 
it regulates are different2,35.  With its ability to recruit remodeling complexes, it may act 
as a glial pioneer factor, making the chromatin accessible to other regulatory factors2. 
In addition to the factors responsible for upregulation of myelin genes, 
downregulation of inhibitory factors is necessary for the maturation of SCs and 
subsequent myelination.  For instance, Notch signaling has been found to inhibit 
myelination, but also to promote maturation of SC precursors and promote their 
proliferation36.  Additional negative regulators of myelination are cJun37 and Sox238.  
Interestingly, there exist a reciprocal regulation between these negative regulators and 
Egr236-38, suggesting that their respective expression levels may be able to regulate 
myelin gene expression.  More recently, Zeb2 has been identified as a transcription factor 
responsible for downregulation of Sox2 and inhibiting Notch signaling by repressing 
Hey2 expression.  Zeb2 mutants failed to downregulate inhibitors of myelination, and 
displayed radial sorting deficits39,40.  The function of micro RNAs in SC differentiation is 
still not very well understood.  Conditional knockout studies of Dicer have demonstrated 
their involvement in myelin regulation41,42, and groups of micro RNAs show expression 
patterns suggesting different roles at the different stages of myelination.  A link between 
gene regulation by micro RNAs and key SC transcription factors has further been 
suggested to occur through direct regulation of micro RNA expression by Sox1043. 
From the perspective of cell engineering and promoting maturation through 
overexpression of some key transcription factors, there are a few considerations to be 
made given the above discussion.  First, there is a core unit of transcription factors that 
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constitute the feed-forward cascade to the extent that it is known today, namely Sox10, 
Oct6, and Egr2, with Brn2 believed to serve a largely redundant role to Oct617,20.  The 
end-point of this cascade is the upregulation of myelin transcripts by Sox10 and Egr2, as 
well as the downregulation of some key inhibitors.  Second, these factors recruit other 
components of gene regulation and possibly epigenetic modification to their target sites, 
highlighting the fact that all such factors also need to be present for the full function to be 
manifested.  Third, the timing of myelination also depends on downregulation of its 
inhibitors.  The regulation of some of the key components necessary for this to happen, 
e.g. Zeb2, is not fully understood in the context of SC myelination, and it is therefore 
unknown if they are part of the same signaling axis that regulates the Sox10, Oct6, Egr2 
cascade, or if they require additional signaling cascades to be activated.  What this means 
is that any derived human SC, be that through stem cell reprogramming, direct 
conversion or transdifferentiation, will have to have these additional components in place, 
as well as the capability to express receptors for functional axon-SC communication. The 
success therefore is highly dependent on the underlying cell preparation quality and 
resemblance to primary SCs, the factors necessary are likely differentiation stage specific, 
and the epigenetic regulation of chromatin accessibility likely to play a role for the 
binding of certain transcription factors for their gene regulation.  This becomes apparent 
from the fact that these factors serve other functions and have other targets in other cell 
types, and dysregulated cells may have unintended or failed target gene regulations from 
the overexpression of these transcription factors.  As pointed out above, Sox10 serves 
similar functions in oligodendrocyte development as it does in SC development, but 
regulates, at least in part, other genes2,34,35.  Oct6 is involved in keratinocyte 
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development44, Egr2 in rhombomere patterning45,46, and Brn2 takes part in cortical layer 
II, III and V neuronal subtype specification47,48 and has been used for neuronal induction 
in cell programming49,50, just to name a few examples.  To expect overexpression of a 
few key transcription factors to reach fully functional, myelinating SCs may therefore 
seem like a tall order.  There is however some respite from the fact that some related 
transcription factors have the key regulatory domains conserved19,51, and the gene 
regulatory network thereby has some plasticity in its composition.  Also, as described in 
Chapter 1, this is one of the most common approaches used in cell reprogramming.  It has 
also been used in some cases of subtype specification, e.g. for neuronal subtypes52,  and 
one may argue that myelination is the SC equivalent of subtype specification between 
myelinating and non-myelinating SCs. 
In this chapter, we first present a set of experiments to determine if transcription 
factor overexpression can improve the myelination frequency from SCs.  This was done 
through overexpression studies in primary rat and mouse SCs, thus constituting a model 
in which myelination for sure can occur.  Our results suggest that overexpression of Egr2 
may indeed enhance myelination frequency even in primary SCs.  We also present some 
preliminary results on human stem cell-derived SCs, although no successful 
functionalization has been observed.  The fact that the cells did not show upregulation of 
known target genes argues that additional factors were not functionally present.  The 
reason for this can range from the use of differentiation stage inappropriate factors, to the 
underlying cell preparation lacking a true SC identity. 
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3.2 Results and Discussion 
3.2.1 Overexpression of Egr2 enhances the myelination frequency in 
primary Schwann cells 
As the key players in peripheral nerve regeneration, SCs have gained much 
attention for nerve regeneration cell therapies in both peripheral and central nervous 
system applications. Upon acute injuries to the peripheral nervous system, they become 
activated and transdifferentiate into a pro-regenerative phenotype that secretes 
neurotrophic factors, clear myelin debris through autophagocytosis and recruitment of 
macrophages, organize into guiding structures within existing channels of basal lamina to 
what are called bands of Büngner, and ultimately remyelinate the regenerating axons, 
again taking on a mature phenotype 53. Out of these attributes, remyelination and trophic 
support for recruitment of immune cells and axon guidance are key for cell therapies.  
Remyelination may be compromised, and can be especially hard to obtain at high 
efficiency using SCs derived through lineage reprogramming 54-56. One possible approach 
to obtain highly functional, remyelinating SCs, is to harness the transcription factors that 
control the cell-intrinsic process of myelination, as outlined previously in this chapter.  
As we do not know if the human cell preparations have all the additional components 
present required for the key transcription factors to take effect, we turned to a proof-of-
concept study in primary rat SCs.  In this system, the cells are known to be able to 
myelinate, and functionalizing effects from transcription factor overexpression may be 
seen as an increase in the fraction of cells partaking in myelination.  Thus the system 
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allows us to study effects of overexpression in a context where arguably all other 
components are available or can be activated. 
To test if overexpression of the core factors of the feed-forward cascade (Sox10, 
Oct6, Brn2 and Egr2) could potentiate myelination, we isolated and purified primary rat 
SCs from postnatal day 5 pup sciatic nerves (Figure 3-1), transduced them with a nuclear 
GFP lentiviral vector plus vectors for one or all of the above four factors and seeded them 
onto purified sensory neurons isolated from embryonic day 14.5 rat dorsal root ganglia. 
Compared with cells transduced with the nuclear GFP vector alone, only the group co-
transduced with Egr2, but none of the other combinations, showed an increased number 
of myelin fragments (Figure 3-2A and B). Closer examination however showed a 
relatively poor overlap of GFP+ cells with the myelin segments (Figure 3-2B). This could 
be due to poor co-transduction, but could also indicate that viral transduction itself is 
detrimental to myelination, and that the effects were not directly related to the 
overexpression of Egr2. We therefore used cells transduced with lentiviruses carrying 
Egr2 with C-terminal epitope tags (Egr2-Myc-DDK), which allowed us to directly 
compare cells expressing the transgene to naïve, non-transduced cells. This experiment 
confirmed that Egr2-overexpressing cells myelinate at a higher frequency than naïve, 
non-transduced cells (Figure 3-2C), while transduction with nuclear GFP had no 
observable effect over naïve cells (Figure 3-3). An EdU assay carried out two days after 
myelination had been induced by the addition of ascorbic acid (five days total into the co-
culture period) showed a decreased mitotic activity in the Egr2-transduced cells (Figure 
3-2D and E), in line with in vivo reports22,57. This also confirms that the enhanced 
myelination was indeed a true functionalization, and not a positive selection of the 
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transduced cells, which would have instead been related to an increase in proliferation of 
Egr2-transduced cells. Only limited cell death was observed for all groups over the 
period of the co-culture, and a TUNEL assay carried out over the same time of co-culture 
confirmed a very low and comparable level of cell death between naïve and Egr2-
transduced cells (Figure 3-2F). Thus, cell death through ER stress was not greatly 
manifested in our model of Egr2 overexpression. Taken together, these results show that 
overexpression of Egr2 can enhance the in vitro myelination frequency of primary SCs. 
3.2.2 Egr2 overexpression does not induce upregulation of known target 
genes in human pluripotent stem cell-derived SC precursors under 
configurations tested 
Encouraged by the in vitro results from primary rat SCs, we tested if Egr2 
overexpression could promote myelination in SC precursor-like cells derived from the 
iPS cell line BC158,59.  The cells were transduced with lentiviruses carrying a bi-cistronic 
expression vector for mCherry and Egr2 (hereafter referred to as mCherry-Egr2), and a 
control transfection with mCherry alone at the same viral titer was carried out in parallel.  
Three days after transduction, most of the cells in the mCherry-Egr2 group were dead, 
and an additional three days after this all the cells in this group were dead, while cells 
receiving the mCherry control vector were alive and robustly transduced (Figure 3-4).  
Titration the viral dose did not render viable transduced cells (data not shown).  Given 
that the control transduction did not result in cell death, these results suggest that the 
overexpression of Egr2 is responsible it. 
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Previous reports using primary murine SCs have observed an upregulation of 
Egr2 with associated ER stress response upon treatment with retinoic acid both in 
monocultures and in co-cultures with sensory neurons.  Interestingly, the study observed 
the induction of CHOP expression60.  This is a transcription factor that induces 
expression of pro-apoptotic Bcl proteins.  The effects of pro-apoptotic Bcl proteins can be 
mitigated by expression of anti-apoptotic Bcl proteins, such as Bcl-xL61.  Overexpression 
of this factor in SCs has furthermore been able to prevent their apoptosis induced by high 
levels of glucose62.  To test if overexpression of Bcl-xL could rescue the cells from the 
apoptosis induced by Egr2 overexpression, and allow it to functionalize the cells, we 
cloned a multi-cistronic lentiviral expression vector containing mCherry, Egr2, and Bcl-
xL.  The constructs were confirmed on HEK 293T cells, that expressed mCherry upon 
transduction, and Western blot revealed the expression of the expected protein products 
(Figure 5).  Transduction of hESC-derived SCPs did not induce apoptosis when Bcl-xL 
was co-expressed.  Analysis of the mRNA expression profiles further showed a robust 
upregulation of Egr2 transcripts, but none of previously identified target genes63 showed 
any significant regulation (Figure 3-6).  These results suggest that at least this preparation 
of ESC-derived SCs was not amenable to induction into a myelinating phenotype by 





Figure 3-1 Isolated primary rat SCs are essentially pure and express canonical SC markers. 
(A) S100β, (B) GFAP, and (C) p75NTR expression was confirmed in isolated SCs after purification.  Scale 




Figure 3-2 Enhanced myelination frequency through Egr2 transduction of rat Schwann cells in co-
culture with rat DRG neurons. 
(A-B) Increased number of myelin segments detected in Egr2-transduced group compared to Gfp only 
transduction, but not for the other factors Sox10, Oct6 or Brn2. (C) Cells transduced with Egr2-Myc-DDK 
vector showed an increased myelination frequency compared to naïve, non-transduced cells. (D-E) 
Reduced proliferation seen by EdU assay over the first two days after addition of ascorbic acid to the co-
culture seen in Egr2-transduced Schwann cells (S100β+ fraction). (F) No significant difference in cell 
apoptosis between Egr2-transduced and naïve Schwann cells detected through TUNEL assay at day 2 after 
addition of ascorbic acid to co-cultures (S100β+ fraction). Scale bars = 100 µm. * P<0.05. *** P<0.0001. 




Figure 3-3 Lentiviral transduction with a GFP control vector does not affect SCs in co-culture with 
DRG neurons. 
No difference was observed between GFP-transduced and naïve cells in terms of (A) myelination 
frequency, (B) proliferation (S100β+ fraction) or (C) apoptosis (S100β+ fraction) as evaluated at the same 




Figure 3-4 Overexpression of Egr2 induces apoptosis in human pluripotent stem cell-derived SC 
precursors. 
Left: Egr2 overexpression causes widespread cell death in BC1-cell derived Schwann cell precursor like 
cells, while cells transduced with a control vector survived (day 6).  Right: Almost all control cells 




Figure 3-5 Confirmation of correct protein products in mCherry, Egr2 and Bcl-xL multicistronic 
expression vectors. 
Western blot analysis of protein lysates from HEK 293T cells either as naïve cells, transduced to 
overexpress mCherry-Bcl-xL, or mCherry-Egr2-Bcl-xL. (A) Probing for Bcl-xL revealed expression of the 
transgene in the expected samples.  (B) Probing with anti-2A peptide revealed the expected products for (<) 
Egr2, and (<<)mCherry. * indicates a non-specific band detected above 70 kDa. Probing against tubulin 
was used as a loading control in both cases.  Viral dose was normalized in (B) but not in (A), explaining the 
higher Bcl-xL expression observed for mCherry-Bcl-xL construct.  These blots demonstrate that the viruses 




Figure 3-6 Overexpression of Egr2 does not regulate known target transcripts in human pluripotent 
stem cell-derived SC precursors. 
qRT-PCR results for transcripts known to be (A) positively regulated and (B) negatively regulated by Egr2, 
as analyzed at three days post-transduction with either control (mCherry), mCherry-Bcl-xL, or mCherry-
Egr2-Bcl-xL lentiviral vectors, upon confirmation of reporter gene expression. Atp5b and Ube4a were used 
as reference genes upon determination of the most stable combination using the geNorm algorithm. n = 3 






Table 3-1 Antibodies used for immunocytochemistry 
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3.5 Materials and Methods 
3.5.1 Cloning, production and titration of lentiviral vectors 
Gateway entry clones for human Sox10 (NM_006941.3), Brn2 (BC051699.1), and 
Egr2 (NM_000399.2) were obtained from the Johns Hopkins University High 
Throughput Biology Center.  Human Oct6 (NM_002699.3) was amplified by PCR from a 
TrueClone cDNA vector (Origene, plasmid SC317737, Rockville, MD, USA) using Q5 
High-Fidelity Polymerase with the forward primer (5’- GCG AAT TCG GCG GCA TG -
3’) and reverse primer (5’- CAA TCT AGA TCA CTG CAC TGA GCC GG -3’), and 
cloned into pENTR1A no ccDB (w48-1), a gift from Eric Campeau (Addgene plasmid 
#17398, Cambridge, MA, USA), between the EcoRI and XbaI sites using the Rapid DNA 
Ligation Kit (Roche, Basel, Switzerland).  Myc-DDK (DDK is also known as a FLAG 
tag) entry clones for Egr2 were created by Gibson assembly with the PCR product from 
an Egr2-Myc-DDK containing plasmid (Origene RC212183, NM_000399.2) using 
forward primer (5’- CTG GAT CCG GTA CCG ATC GCC ATG ATG ACC GCC -3’) 
and reverse primer (5’- TCG AGT GCG GCC GCG TTA AAC CTT ATC GTC GTC 
ATC CTT G -3’) as insert and pENTR1A no ccDB (w48-1) digested with EcoRI-HF 
(NEB, Ipswich, MA, USA) as the backbone, and assembled using the Gibson Assembly 
Master Mix (NEB).  Transfer vectors were then created through an LR clonase II reaction 
(ThermoFisher) into pLenti CMV Blast DEST (706-1), a gift from Eric Campeau 
(Addgene plasmid # 17451).  A bi-cistronic transfer vector for Egr2 and mCherry using a 
2A peptide was created by cloning Egr2 from the above transfer vector by PCR using 
forward primer (5'- TAT ATC TAG AAT GAT GAC CGC CAA GGC CGT AG -3') and 
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reverse primer (5'- TAT AGG ATC CCT ATC AAG GTG TCC GGG TCC GAG -3'), 
and ligating between the XbaI and BamHI sites of pUltra-hot, a gift from Malcolm 
Moore (Addgene plasmid #24130).  A GFP with a nuclear localization signal (nuclear 
GFP) in the pLenti-CMV Blast DEST backbone was a gift from Donald Zack.  All 
constructs had the CDS and insertion sites verified by Sanger DNA sequencing (Genewiz, 
South Plainfield, NJ, USA), and were expanded in Stbl3 cell hosts (Thermo Fisher 
Scientific, Lafayette, CO, USA). 
For lentivirus production, HEK 293T cells, a gift from Donald Zack, were plated 
at 4 million live cells per plate in 8 ml of DMEM/F12 supplemented with 10% HI-FBS, 
1x MEM non-essential amino acid solution, 1 mM sodium puryvate, penicillin (100 
U/ml) and streptomycin (100 µg/ml, all from Thermo Fisher),  onto poly-(D)-lysine-
coated 10 cm dishes (Sigma-Aldrich, St. Louis, MI, USA). The next day, 15 µg/plate of 
the VSV-G envelope plasmid pMD2.g (Addgene plasmid #12259), 6 µg/plate of 
pMDLg/pRRE (Addgene plasmid #12251), 6 µg/plate pRSV-Rev (Addgene plasmid 
#12253), all gifts from Didier Trono, as well as 15 µg/plate of respective transfer vector 
was combined to a final plasmid concentration of 100 µg/ml.  Then, linear 
poly(ethyleneimine) (Polymer Chemistry Innovations, Inc., Vista, CA, USA) was added 
to the mixture at a nitrogen to phosphate molar ratio of 6, and the polyplexes added to the 
cells for 4 hours before the media was exchanged.  The following day, 10 mM sodium 
butyrate (Sigma-Aldrich) was added to the media.  Two days after transfection, the 
supernatant was collected and viruses concentrated using Lenti-X concentrator 
(Clonetech, Palo Alto, CA, USA) according to the manufacturer’s instructions, aliquots 
prepared in PBS and stored at  -80oC. 
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To determine the multiplicity of infection (MOI), purified primary rat SCs were 
infected with a serial 1:10 dilution of the nuclear GFP lentivirus in the presence of 8 
µg/ml of polybrene (Sigma-Aldrich) over night, then detached four days after 
transduction using TrypLE Express (Thermo Fisher) and fixed with 1% 
paraformaldehyde in PBS before analyzing transduction efficiency by flow cytometry.  
Cells were considered positive when their expression level was above 99.9% of the cells 
in a non-transduced control sample.  MOI was calculated for samples with a 2 – 20% 
transduction efficiency.  After this, titration was performed using a PCR kit (Applied 
Biological Materials, Richmond, BC, Canada) on all other constructs and batches of 
lentiviruses, and their MOI determined by their relative viral titer to the nuclear GFP 
vector. 
3.5.2 Western blot 
HEK 293T cells were transduced with lentiviral vectors in the presence of 8 µg/ml 
polybrene (Sigma-Aldrich) over night.  Once the cells displayed expression of the 
fluorescent reporter, they were washed with PBS, lysed on ice with 1x RIPA buffer (Cell 
Signaling Technology, Beverly, MA, USA), and 1x protease inhibitor cocktail (Sigma-
Aldrich) in PBS for 5 minutes.  The plates were scraped using a rubber policeman, and 
the lysate transferred to a pre-chilled tube.  Following a brief sonication, samples were 
centrifuged at 14 000 xg for 10 minutes at 4oC.  The supernatant was collected, aliquots 
prepared and frozen down at -80oC until further analysis.  The protein concentration was 
determined using a BCA protein assay (Pierce, Rockford, IL, USA) according to 
manufacturer’s protocol. 
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Samples were thawed on ice and dissolved in 1x Laemmli’s buffer with loading 
dye (Bio-Rad, Richmond, CA) and an additional 5% β-mercapto ethanol (Sigma-Aldrich) 
in PBS and samples denatured for 5-10 min at 95oC.  20 µg protein was loaded per lane 
into 4-15% TGX gels (Bio-Rad) in 1x TGS buffer.  PageRuler Plus pre-stained ladder 
(Thermo Fisher) was used for molecular weight determination.  Gel was run at 30 V 
loading voltage followed by 200 V running voltage until loading dye reached the bottom 
of the gel.  Gels were transferred to PVDF membranes using TransBlot Turbo systems 
and protocols (Bio-Rad), before rinsing in TBS with 0.1 % Tween 20 (TBST). 
Blots were blocked with 5% non-fat dry milk (Bio-Rad) in TBST for 1 hour, 
before incubating with rabbit primary antibodies against 2A peptide (ABS31, 1:10000 
dilution, Millipore, Billerica, MA, USA), or Bcl-xL (catalogue number 2764, 1:1000 
dilution, Cell Signaling Technology) in 5% non-fat dry milk in TBST over night.  Blots 
were then rinsed 5 times briefly and washed 3 times over 10 minutes with TBST before 
incubating with HRP-conjugated donkey anti-rabbit antibody (A16035, 1:10000 dilution, 
Thermo Fisher) for 1 hour at room temperature in above blocking buffer before washing 
as above. 
Blots were developed using ECL reagent (GE Healthcare, Waukesha, WI, USA) 
for 1 minute and imaged using LAS 4000 system (GE Healthcare). 
HRP was then deactivated by incubation with 30% hydrogen peroxide (Sigma-
Aldrich) for 20 min at 37oC, and inactivation confirmed using ECL development as 
above. 
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Blots were then probed with a loading control, mouse anti-tubulin (Sigma-
Aldrich) as above, with secondary HRP-conjugated goat anti mouse (A16017, 1:10000 
dilution, Thermo Fisher) with incubations and development done the same as above. 
3.5.3 Cell isolation and purification 
Primary rat SCs were isolated from Sprague Dawley rat postnatal day 4 pups 
using the methods described by Brockes 64 with slight modifications. Briefly, sciatic 
nerves were dissected and epineurium removed. The nerves were then digested with 
collagenase type I (Thermo Fisher) at 3 mg/ml in L-15 medium for 45 minutes at 37oC, 
further treated with 0.375 mg/ml DNase (Thermo Fisher) and 0.0625% Trypsin EDTA 
(Thermo Fisher, diluted from 0.25% solution) for 15 min at 37oC. The reaction was 
stopped by addition of DMEM containing 10% HI-FBS, nerves washed with L-15, and 
then titurated to release the cells and plated onto TCPS coated with collagen (Nutragen, 
1:30 dilution, Advanced BioMatrix, Poway, CA, USA) in DMEM with high glucose, no 
sodium puryvate (Thermo Fisher), 10 µg/ml of piperacillin and ciprofloxacin (Sigma-
Aldrich) and 10% HI-FBS (Thermo Fisher) (media composition hereafter referred to as 
D10). The day after plating, Ara-c was added to the media at 10 µM for 2-3 days, after 
which cells were cultured in D10 with 200 ug/ml of bovine pituitary extract and 2 µM 
forskolin (both from Sigma-Aldrich). Cells were passaged by detaching with Accutase 
(SigmaAldrich), incubated with anti-Thy1 from hybridoma supernatant at a 1:100 
dilution (TIB-103, American Type Culture Collection, Manassas, VA, USA) for 30 
minutes at 37oC, washed with DMEM and incubated with rabbit complement diluted 1:8 
(MP Biomedicals, Aurora, OH, USA), before plating at a 1:2 – 1:3 seeding ratio.  Media 
was exchanged three times per week. 
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Mice with eGFP expression under the proteolipid protein promoter were gifts 
from Jeff Rothstein, originally derived in the lab of Wendy Macklin 65.  Primary mouse 
SCs were isolated in the same way from the sciatic, median and ulnar nerves of P4 Plp-
eGFP pups, except that the epineurium was not removed and no Ara-C or anti-Thy1 
treatment was performed. Transgene expression was confirmed in biopsies by 
epifluorescent microscopy prior to cell isolation, and only positive pups used.  Nerves 
from the positive pups of one litter were pooled prior to digestion. 
Sensory neurons were isolated from Sprague Dawley rat day 14.5 embryo dorsal 
root ganglia (DRG). After dissection of the DRGs, they were transferred into L-15 media 
to which 100 µl of 10 mg/ml collagenase type I, 40 µl of 0.25% Trypsin-EDTA, and 15 
µl of 25 mg/ml DNase was added. The tissue was incubated at 37oC for 45 min, washed 
twice and then plated onto 12 mm PDL/laminin-coated glass slides (Thermo Fisher) at 30 
000 cells in a 100 µl droplet of Neurobasal media supplemented with 1x B27 supplement, 
1x Glutamax (Thermo Fisher), 50 ng/ml NGF (Alomone Labs, Jerusalem, Israel), and 10 
µg/ml of piperacillin and ciprofloxacin (Sigma-Aldrich).  After 1.5 hours, media was 
added to fill the well.  Cells were purified the next day by adding 10 µM of both uridine 
and 5-fluorodexuridine (FuDR, Sigma-Aldrich) for 2-3 days, kept 2 days in regular 
culture media, followed by another 2 day purification treatment.  After this, mitotic cells 
could no more be observed in the cultures.  Media was exchanged three times per week, 
and the cells underwent at least two media changes after completing the purification 
before initiating co-culture experiments. 
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3.5.4 Schwann cell and DRG neuron co-cultures 
6 well plates of TCPS were coated with collagen (Nutragen, 1:30 dilution, 
Advanced BioMatrix), and purified rat SCs at passage 4 – 6 after isolation were seeded at 
100 000 cells/well.  The following day, 8 µg/ml of polybrene (Sigma-Aldrich) was added 
to the media together with the lentiviral vectors used for the respective assay (see below).  
The next day, the media was removed, cells washed two times with PBS, and then 
detached using Accutase (Sigma-Aldrich).  The cells from one transduced well were 
seeded onto four cover slips with purified DRG neurons in media composed of EMEM 
(Quality Biological), 4 mg/ml D-glucose (Sigma-Aldrich), 50 ng/ml NGF, and 1% HI-
FBS.  After three days of co-culture, half the media volume was replaces and ascorbic 
acid supplemented to a final concentration of 50 µg/ml to induce myelination. 
Approximately half the media was replaced daily throughout the time of the co-culture, 
adjusting for some evaporation, with the ascorbic acid prepared fresh every time from 
powder.  The half media change was done not to expose the cells directly to the ambient 
air, but to keep them constantly hydrated. 
For comparing the effects of the different transcription factors, the cells received 
the vectors at an MOI of 5 for each vector used, except for Sox10, which was given at an 
MOI of 1.17 due to poor viral titers.  Groups included nuclear Gfp vector alone, or the 
nuclear Gfp vector plus one or all of the transcription factors as pooled viral solutions.  
Samples were collected at three weeks after the first ascorbic acid addition. 
To further investigate the effects of Egr2, cells were treated as above with 
lentiviruses encoding nuclear Gfp or Egr2-Myc-DDK (i.e. not combining the vectors) at 
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an MOI of 1, and compared to naïve, non-transduced cells.  Samples were collected at 
three weeks after the first addition of ascorbic acid.  Egr2-transduced cells were 
identified by the presence of the Myc epitope tag. This treatment was also used for the 
EdU and TUNEL assays, but at shorter time points (see below). 
3.5.5 EdU incorporation assay 
SC and DRG co-cultures were pulse-labeled by replacing half the media volume 
with fresh media containing 20 µM 5-ethynyl-2-deoxyuridine during the first and second 
media change at which ascorbic acid was also added.  This was only done to samples 
used for proliferation assays: SCs transduced with the Egr2-Myc-DDK vector, nuclear-
GFP, and naïve cells. Two days after the first addition, cells were fixed using 4% 
paraformaldehyde in PBS for 10 minutes at room temperature, and stored in PBS at 4oC 
until staining.  The cells were then labeled using the Click-iT® 555-EdU assay (Thermo 
Fisher), before staining for S100β with an Alexa Fluor 647 secondary as described below.  
Four samples per group were used, imaging two regions per sample and counting only 
S100β-labeled cells to specifically detect SCs.  Samples were also stained with the anti-
Myc antibody with an Alexa Fluor 488 secondary, but the anti-Myc had gone bad and 
this channel was excluded from the analysis. 
3.5.6 TUNEL assay 
SC and DRG co-cultures, for SCs transduced with the Egr2-Myc-DDK vector, 
nuclear-GFP, and naïve cells, as well as controls containing only DRG cells, were fixed 
with 4% paraformaldehyde in PBS for 10 min at room temperature, before immediately 
staining with the ApopTag Red kit (Millipore) according to the manufacturer’s 
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instructions.  Negative control samples using isolated DRG cells were prepared by 
omitting the TdT enzyme step. After this stain, the samples were stained as described for 
the EdU assay, again not using the anti-Myc stain in the analysis.  
3.5.7 Immunocytochemistry 
At the completion of the assays, samples were fixed with 4% paraformaldehyde in 
PBS for 10 min at room temperature, and either directly processed or stored at 4oC in 
PBS until staining.  Samples were then permeabilized using 0.3% Triton X-100 (Sigma-
Aldrich) in PBS for 20 min at room temperature, rinsed three times with PBS, and then 
blocked for one hour in PBS containing 5% normal goat serum (Sigma-Aldrich).  
Primary antibody incubations were carried out over night at 4oC in the blocking buffer, 
with antibody dilutions according to Table 3-1.  Samples were then washed five times 
over 25 min with PBS, and incubated with secondary antibodies for one hour at room 
temperature.  Apart from a Cy3-conjugated goat anti-mouse IgG2b antibody (Jackson 
Immuno Research Laboratories Inc., West Grove, PA, USA) used at a 1:200 dilution, all 
other secondaries were Alexa Fluor conjugated and raised in goat used at a 1:500 dilution 
(Thermo Fisher) in blocking buffer. The incubation was followed by five washes over 25 
min with PBS, and samples were then mounted using ProLong Diamond Anti-Fade with 
DAPI (Thermo Fisher).  Imaging was performed using a Zeiss LSM 780 system, and 
images presented are maximum intensity projections from confocal Z-stacks. 
3.5.8 Statistical analysis 
Statistical analysis was carried out using R (R Core Team 2015), and GraphPad 
Prism (GraphPad Software, La Jolla, CA, USA).  Effects of the different transcription 
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factors were compared to the Gfp only control group (Figure 3-2A) using Dunnett's 
multiple comparison test.  Direct comparisons of myelination frequency, EdU 
incorporation and TUNEL assays between groups were performed using Fisher’s exact 
test, and 95% confidence intervals for the individual means, as depicted in the graphs, 
were computed using a binomial test.  Results were considered statistically significant for 
P<0.05. 
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CHAPTER 4 - USE OF OLIGODENDROCYTE 
PROGENITOR CELLS IN PERIPHERAL NERVE 
REGENERATION CELL THERAPIES 
4.1 Introduction 
Compared to the central nervous system (CNS), the peripheral nervous system 
(PNS) has a stronger inherent capability to regenerate.  This is in large accredited to the 
myelinating glia cells in the PNS, the Schwann cells (SCs), which upon injury 
transdifferentiate into an activated phenotype that assists in myelin debris clearance, 
trophic support and axonal guidance, and eventual remyelination of the regenerating 
axons1.  For the treatment of PNS injuries, much effort has been put forth to do away 
with the current gold standard for management of large nerve injuries, the autograft, 
which implies that suitable nerve tissue deemed to be less important has to be sacrificed 
and is associated with complications such as donor site morbidity and a shortage of 
suitable donor tissue2.  The realization that endogenous SCs have a limited ability to 
populate large acellular grafts due to eventual senescence3, and that primary autologous 
SCs are as hard to come by as the initial donor tissue itself, has led to much effort to 
derive SC analogs from stem cell sources to be used in cell therapies in conjunction with 
decellularized or synthetic nerve guides4.  As opposed to other cells explored, e.g. neural 
or mesenchymal stem cells that may provide trophic support5,6, SCs are unique from the 
perspective that they are the cells of the PNS capable of regenerative remyelination. 
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In the CNS, oligodendrocytes myelinate axons, and upon injury the 
oligodendrocyte precursor cells (OPCs) become activated to produce oligodendrocytes 
capable of remyelinating axons7-12.  While progress is being made in cell preparation 
techniques for both SCs13-22 and OPCs23-30, only protocols for human pluripotent stem 
cell-derived OPCs have received FDA clearance for phase I clinical trials31. 
To date and to the best of our knowledge, there has not been any study 
investigating the feasibility of using oligodendrocytes for PNS therapies.  We therefore 
set out to test if the PNS microenvironment can support primary OPCs, and if so, if the 
cells can serve a function in regenerative myelination and cell therapies for PNS injuries.  
Heterotopic engraftment of mouse OPCs isolated from perinatal brains showed a good 
survival in cryolesioned tibial nerves of non-obese diabetic (NOD)-severe combined 
immunodeficiency (SCID) mice, with multiple cells engaged in myelination one month 
after engraftment.  Interestingly, the myelinating cells were predominantly found to be of 
a SC-like phenotype, suggesting that the microenvironment not only supports the survival 
of the cells and remyelination of the axons, but also that the cells undertake a phenotype 
appropriate to the PNS, expressing periaxin, a component of PNS but not CNS myelin32, 
the SC marker S100β, and forming a one-to-one relation closely approximated to the 
axons being myelinated.  The engrafted cells further lacked expression of 
oligodendrocyte lineage markers Olig2 and myelinating oligodendrocyte glycoprotein 
(MOG).  Our results are thus the first to demonstrate that cells of the oligodendroglia 
lineage can be effectively used in peripheral nerve cell therapies, and that the PNS 
microenvironment promotes their differentiation into a SC-like phenotype. 
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4.2 Results 
4.2.1 OPCs engraft and remyelinate in the PNS 
To test whether or not OPCs can engraft and remyelinate in the PNS 
microenvironment, we performed heterotopic engraftment of acutely isolated OPCs from 
postnatal day 4 – 5 mouse pups brains expressing an eGFP reporter under the proteolipid 
protein promoter (Plp-eGFP mice)33, and purified using magnetic activated cell sorting 
against the O4 antigen, into cryolesioned tibial nerves of NOD/SCID mice.  
Cryolesioning, or cryoanalgesia, was used as a way to kill the host cells in situ34 and 
reduce competitive remyelination from the host SCs while preserving some of the native 
nerve architecture and basal lamina tracts35-38  This is a method used clinically for long-
term pain management38,39.  The cell preparations were predominantly of an immature 
oligodendrocyte phenotype, with the majority of the cells expressing O4, A2B5 and 
Olig2 (Figure 4-1).  One month post engraftment, numerous eGFP+ cells were found 
distributed throughout the lesion site (Figure 4-2A).  As the eGFP expression indicated 
Plp promoter activity, a major component of myelin, it indicated not only that the cells 
had survived, but also that these cells had obtained a more mature phenotype.  Staining 
against myelin basic protein and neurofilament revealed numerous cells engaged in 
myelination of the regenerating axons (Figure 4-2B-C). 
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4.2.2 OPCs engrafted into the PNS transdifferentiate into myelinating 
SC-like cells 
The observation that myelinating OPCs were found to closely associate with their 
axons (Figure 4-2B) made us ask whether or not they had undertaken a SC-like 
phenotype.  SCs namely undergo a process known as radial sorting, where the pro-
myelinating SCs associate with large caliber axons to be remyelinated in a one-to-one 
relation, as opposed to oligodendrocytes which myelinate multiple axons40.  Numerous 
observations have shown myelination of CNS axons by SCs in certain focal injury 
models41-43 as well as in multiple sclerosis patients44,45, and recent lineage tracing 
experiments established that these cells are derived from local OPCs43.  To determine if 
the myelinating cells were of a SC phenotype, we co-stained for S100β and MBP.  64 % 
of the MBP+ cells were also S100β positive (Figure 4-3A-C), indicating that they were of 
a SC-like phenotype.  While astrocytes also express S100β, and OPCs can differentiate 
into astrocytes46, an astrocyte fate in these cells can be excluded based upon their 
engagement in myelination.  To further confirm their SC-like identity, we quantified the 
percent of ensheathing graft-derived cells that were positive for periaxin.  93% of graft-
derived cells associated with axons were found positive for periaxin (Figure 4-3D-E).  
We further examined the expression of myelinating oligodendrocyte glycoprotein (MOG) 
to understand if the myelinating or pro-myelinating cells would express a marker for 
CNS myelin.  Only one out of the 187 analyzed Plp-eGFP+ cells were found positive for 
MOG, while control stains of adult mouse corpus callosum were clearly positive (data not 
shown).  None of the cells expressing the Plp-eGFP reporter engrafted into the 
cryolesioned tibial nerves were found to express the oligodendrocyte lineage marker 
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Olig2 (0 out of 597 cells analyzed), while it was readily detected in eGFP+ cells in the 
cortex of adult Plp-eGFP mice (data not shown).  Collectively, these results argue that the 
myelinating graft-derived cells are predominantly of a SC-like identity. 
4.3 Discussion 
To the best of our knowledge, this constitutes the first report of OPCs capable of 
engrafting and remyelinating axons in a peripheral nerve injury model.  With recent 
advances in lineage reprogramming techniques for OPCs23-30, our findings highlight them 
as new candidates for cell therapies to treat peripheral nerve injuries.  This is a highly 
relevant proof-of-concept for cell therapies, as OPC preparation methods from human 
pluripotent stem cells have progressed to the point where they are evaluated in clinical 
trials, and have been shown capable of myelinating axons31. 
Our results indicate that the PNS microenvironment causes them to undertake a 
SC-like phenotype.  With 93% of the cells engaging axons expressing the PNS myelin 
component periaxin suggests that the cells undertake a myelinating phenotype 
appropriate to the PNS with high efficiency.  Out of the Plp-eGFP reporter and MBP 
double-positive cells, 64% also expressed the mature SC marker S100β.  While this is the 
first report of the PNS microenvironment supporting survival and SC-like differentiation 
of OPC progeny, the appearance of SCs in the CNS has been known for a long time in 
models of focal demyelination41-43 as well as in patients suffering from multiple 
sclerosis44,45.  As the SC appeared at the center of the lesion site from where astrocytes 
had been ablated, but that oligodendrocyte myelination was seen in the periphery of the 
lesion site where astrocytes were once again present, it was believed that astrocytes 
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maintain a CNS to PNS glia boundary, restricting SC migration into the CNS41.  Further 
evidence for the involvement of astrocytes in determining the eventual myelinating 
phenotype in CNS lesions came from OPC engraftment studies into focal demyelination 
of the spinal cord.  When the population was purified from astrocytes and engrafted into 
ethidium bromide-induced demyelinated lesions, extensive SC myelination was observed.  
However, if the engrafted cells still contained astrocytes, oligodendrocyte myelination 
would predominate47.  The idea that astrocytes act to restrict migration of SCs held true 
when the migration of SCs isolated from male donors were engrafted into lesions in 
female hosts, thereby possible to track by in situ hybridization against the Y-chromosome, 
where the engrafted SCs were contained within an astrocyte boundary.  As pointed out by 
the authors, it is however not certain that the restriction demonstrated by the astrocytes at 
a lesion site like this necessarily translate into other astrocyte-containing areas of the 
CNS48. Another study using the same approach to track the progeny of male donor-
derived PSA-NCAM+ neural precursor cells49, an early glial progenitor which in vitro 
gives rise to mostly astrocytes and oligodendrocytes when transferred to adherent 
substrates50, found the Schwann cell myelination at the site to be graft-derived49.  
Subsequent studies have shown that engraftment of OPCs into demyelinated CNS lesions 
ablated from astrocytes also display SC myelination51,52, and that the SCs observed in this 
setting are graft-derived52.  The CNS however contains multiple cell-types that have been 
shown capable of undertaking a SC-like phenotype, from neuroepithelial stem cells 
present during embryonic development53, to cells present in perinatal and adult tissue 
such as olfactory ensheathing cells54,55, tanycytes, pituicytes56, as well as SCs associated 
with autonomic nerve fibers of large blood vessels.  It is therefore possible that the 
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primary isolates contain a small subpopulation of contaminating cells that account for the 
observed SC-like remyelination.  This also holds true for our study, as these cells are 
known to express the cell surface marker O4 used to purify our cultures54-56.  It is 
however the much more implausible interpretation of the data, as OPCs are a highly 
numerous population.  Even in the adult brain, they constitute 4-5% of the total cell 
population57,58. To solidify whether or not the observed SC-like myelination could be 
OPC-derived was thus studied through lineage tracing experiments in focal 
demyelination models of the spinal cord without any cell engraftment, and found that the 
observed SC-like cells were predominantly, derived from locally recruited OPCs43.  
What is then the connection between astrocytes and their control over the OPC 
fate?  In vitro experiments have shown that astrocyte monolayers secrete factors that 
prevent type-2 astrocyte differentiation of OPCs of the optic nerve59.  This is, at least in 
part, believed to be through their secretion of Noggin, an inhibitor of BMP signaling60-62.  
As neuroepithelial stem cells could be induced to obtain PNS competency though BMP-
2/4 treatment53,  and findings that OPCs and cortical precursors could be induced into 
multipotent stem cells by first exposing them to bFGF followed by BMP63,64, led to the 
proposition that astrocyte depletion in ethidium bromide-induced focal lesions also 
ablated the cell source for Noggin and allowing for activation signaling pathways that 
enable SC differentiation65.  It was later shown that X-ray irradiated ethidium bromide-
induced focal demyelination lesions in the spinal cord indeed had BMP-2/4 expression 
but lacked Noggin, and that transfection of the OPCs with a Noggin expression vector 
prior to engraftment would prevent SC-like differentiation52, much like previous studies 
co-engrafting astrocytes with the OPCs47.  These studies thus argue that inhibition of 
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BMP signaling by astrocyte-derived Noggin maintains the normal fate commitment of 
OPCs into oligodendrocytes.  In the case of peripheral nerve tissue, Noggin is virtually 
absent relative to the levels seen in the brain or spinal cord66.  It is therefore plausible that 
the same mechanisms accounting for the transdifferentiation seen in CNS demyelination 
models are at play also upon heterotopic engraftment into the PNS, although we do not 
have direct evidence for this.  Blocking BMP signaling, e.g. with Noggin, would have 
secondary effects on PNS regeneration as it would act directly on the regenerating axons 
and block their regrowth67,68.  We deemed knockdown of specific BMP receptors in the 
engrafted cells as unfeasible and beyond the scope of this study, as multiple receptor 
combinations and signaling pathways may converge69. 
The lack of Olig2+ cells in our study suggests that the progenitor pool has been 
largely depleted.  This indicates that while the PNS microenvironment can maintain the 
differentiated progeny over the time of our study, long-term maintenance of 
undifferentiated OPCs is very limited.  We see that this could be through two distinct 
mechanisms: direct terminal differentiation of the OPCs, or death of any self-renewing 
OPCs, leaving behind only the differentiated progeny.  It should be stated that we isolated 
the cells from perinatal pups, where the predominant progeny of OPCs in the brain has 
been shown to be mature oligodendrocytes, they still maintain a sizeable fraction of 40% 
OPC progeny70.  The extent to which environmental factors vs. a cell-intrinsic 
predisposition plays a part in this fate commitment is unknown.  While it is true that we 
select for a more mature progeny through O4 expression than the NG2 cell studied by 
Zhu et al.70, O4 cells isolated from perinatal brains can however be propagated in vitro in 
the presence of FGF2 and PDGF-AA71, and results from in vivo studies show that the O4 
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antigen presence is not directly related to a terminal fate commitment, but that O4 cells 
continue to proliferate in the perinatal brain72.  In the uninjured brains of mice, studies 
have shown compelling evidence for both direct fate commitment73, as well as for 
asymmetric division74.  In response to injury, OPCs become activated to proliferate and 
migrate to the lesion site.  Injuries to the CNS trigger both differentiation and self-
renewal of the OPC population11,75-79, and repeated focal brain demyelination does not 
deplete the OPC pool80, which would argue that the normal response maintains a 
population of progenitors.  Focal injuries however rely largely on OPC recruitment from 
adjacent tissue81, which is not present in our PNS model.  Upon chronic demyelination 
through systemic cuprizone administration, continuous treatment depletes the progenitor 
cell pool.  The progressive decline in OPC number suggests that the cells have a 
restricted capacity to recover under continuous pressure to proliferate82.  Therefore, in 
addition to the possibility that OPCs cannot survive undifferentiated in the PNS over long 
periods due to lack of an appropriate niche, depletion of the population may also be due 
to extensive and direct differentiation and exhaustion due to a maintained pressure to 
proliferate. 
We further observed a near complete absence of MOG expressing cells at the 
graft site, suggesting that either differentiation towards mature oligodendrocytes or their 
survival is highly limited in the PNS microenvironment.  As we did observe one MOG+ 
cell at one month post-engraftment, the cells appear to still have an ability to form 
oligodendrocytes, although the efficiency thereof may be limited.  Previous studies in 
optic nerves suggest that oligodendrocyte survival depends upon axon-derived 
support83,84.  This is in contrast to SCs, who become activated upon denervation to 
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proliferate and repair the injury site1.  It is therefore likely that while the PNS 
microenvironment may not prevent oligodendrocyte differentiation of the OPCs, there is 
a selective advantage for the SC-like progeny explaining our observed results. 
Finally, it appears that the niche plays a large role in OPC fate commitment, 
phenotype and function.  All cases where SC-like differentiation of OPCs has been 
observed were associated with significant perturbations of their niche.  This is an 
interesting concept also for CNS regeneration, as the employment of artificial niches may 
direct the differentiation of OPC progeny to facilitate their survival and function in 
regeneration.  Two recent reports have shown axon regeneration in spinal cord injury 
models where hydrogels delivering growth factors were employed85,86.  In one of the 
studies, the hydrogel was used to provide tropic cues to promote axonal extension 
through glial scar tissue.  It is however possible that the growth factors altered the 
phenotype and function of the glial cells.  Interestingly, it was reported that axons grew 
along reactive astrocytes in this setting (Figure 5G in Anderson et al.85), identified by the 
astrocyte marker GFAP.  However, GFAP is also expressed in SCs, but becomes 
suppressed upon myelination40.  It is tempting to speculate that the observed cell may 
have been a pre-myelinating SC associated with the axon, and that the growth factors 
delivered by the hydrogel had provided a niche in which OPCs (or other cells recruited 
from the surrounding tissue) had transdifferentiated into a phenotype supporting 
regeneration.  Likewise, Lu et al.86 used a fibrin gel carrying a cocktail of growth factors 
for the purpose of supporting the survival of the engrafted neural stem cells, but the 
impact of these factors and the artificial niche created by the hydrogel was not considered 
to act upon resident glia.  The knowledge that OPC fate is controlled by its niche should 
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therefore be taken into consideration and investigated as an approach to promote 





Figure 4-1 Expression of oligodendrocyte precursor cell markers was confirmed in isolated cells from 
P4-P5 mouse brains. 
(A-B) O4 staining and cell membrane localization was confirmed in the isolated cells (C-D) A majority of 
the cells also expressed the cell-surface marker A2B5, and (E-F) were positive for the transcription factor 
Olig-2.  Inserts in A-D show orthogonal projections of images at higher magnification.  GFP expression is 




Figure 4-2 Engrafted OPCs survived and remyelinated after engraftment into cryolesioned tibial 
nerves of NOD/SCID mice. 
(A) Plp-eGFP positive cells were found throughout the nerve, and (B-C) were found to engage in 
remyelination of regenerating axons one month after engraftment, as seen in (B) longitudinal  and (C) 
transverse cross-sections.  Arrowheads in (B) indicate graft-derived cells that are closely associated with 
the axons they myelinate.  Arrowheads in (C) show examples of MBP+ graft-derived cells.  Scale bars are 1 




Figure 4-3 OPCs transdifferentiated into a SC-like phenotype upon engraftment into the 
cryolesioned tibial nerves of NOD/SCID mice. 
(A-C)  Co-expression of MBP and S100β in Plp-eGFP+ graft-derived cells.  Arrowheads indicate graft-
derived cells that were double-positive for S100β and MBP, indicating a SC-like phenotype.  (C) 64% of 
the GFP+MBP+ cells were also p S100β+.  (D-E)  The majority of Plp-eGFP+ cells associated with axons 
expressed the peripheral myelin component periaxin.  (E) 93% of axon-associated Plp-eGFP+ cells were 
found positive for periaxin.  (F) 38% of the entire graft-derived population from CAG-GFP donors was 
found positive for MBP.  Error bars in (C, E, F) = 95% confidence intervals.  (C) n = 109 cells analyzed 
between 5 animals.  (E) n = 368 cells analyzed between 4 animals.  (F) n = 2790 cells analyzed between 6 











4.6 Materials and Methods 
4.6.1 Cell isolation 
Donor Plp-eGFP mice derived in Wendy Macklin’s lab33 were a kind gift from 
Jeffrey Rothstein. C57BL/6-Tg(CAG-EGFP)131Osv/LeySopJ (referred to as CAG-GFP) 
male and C57BL/6 wild-type females were obtained from Jackson Laboratories Inc. (Bar 
Harbor, ME, USA).  At postnatal day 4-5, brains from pups positive for the reporter were 
dissected and the olfactory bulbs and spinal cord discarded.  The tissue was dissociated 
using neural tissue disassociation kit (P) (Miltenyi Biotech, Auburn, CA, USA) and O4+ 
cells purified using MACS anti-O4 beads and MS columns (Miltenyi Biotech) according 
to the manufacturer’s instructions.  A subset of the cells were plated onto PDL/laminin-
coated glass cover slips (Corning BioCoat, Thermo Fisher, Waltham, MA, USA) at 40 
000 cells in a 50 µl volume of Bottstein and Sato’s serum-free medium (as described by 
Watkins et al.87, omitting T3) supplemented with 10 ng/ul human recombinant PDGF-
AA (PeproTech, Rocky Hill, NJ, USA).  After 3-4 hours at 37oC, 5% CO2, the cells had 
adhered and the wells were filled.  Cells were fixed for purity assessment the following 
day using 4% paraformaldehyde in PBS for 15 min. 
4.6.2 Immunocytochemistry 
For intracellular antigens, the cells were permeabilized using 0.3% Triton X-100 
(SigmaAldrich, St. Louis, MO, USA) in PBS for 20 min at room temperature.  This was 
not done for surface antigens with extracellular epitopes.  Samples were rinsed thee times 
with PBS prior to blocking for one hour at room temperature using 5% normal goat 
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serum (Sigma-Aldrich) in PBS.  Primary antibodies were incubated over night at 4oC in 
blocking buffer.  Samples were washed five times over 25 min with PBS before 
incubating with AlexaFluor-conjugated secondary antibodies (1:500 dilution, Thermo 
Fisher) for one hour at room temperature.  Samples were once again washed 5 times over 
25 min with PBS and mounted using ProLong Diamond anti-fade with DAPI (Thermo 
Fisher).  Primary antibody omission controls were performed, and sampels imaged using 
an LSM 780 confocal microscope system (Carl Zeiss Microscopy GmbH, Jena, 
Germany). 
4.6.3 Cryolesioning, cell engraftment and tissue processing 
Cell suspensions of acutely isolated cells were prepared in HBSS w/o calcium or 
magnesium (Mediatech, Herndon, VA, USA) and placed on ice until engraftment.  Adult 
male NOD.CB17-Prkdcscid/J mice were obtained from Jackson Laboratories to serve as 
hosts.  Mice under inhalation anesthesia (1-3% isoflurane) had the tibial nerves exposed 
and cryoanalgesia induced just distal to the bifurcation from the sciatic nerve by freezing 
it with a piece of dry ice.  This was repeated three times with thawing in between before 
the nerve was transected just proximal to the cryolesioned site, 2 µl cell suspension 
containing 80 000 cells was injected into the center of the cryolesioned site using a 
Hamilton syringe, and direct nerve anastomosis was performed just proximal to the 
freeze/thaw site before the wound was closed using surgical clips.  Animals were 
monitored for the one month duration of the experiment, displaying normal healing 
behavior without any adverse effects.  After one month, the animals were sacrificed by 
transcardial perfusion, first with PBS and then with a 4% paraformaldehyde solution in 
PBS before the tissue was harvested for 2 hours of post-fixation in 4% paraformaldehyde 
 153 
at 4oC.  Nerves were transferred to 15% sucrose in PBS for 2-3 days at 4oC, followed by 
30% sucrose for the same duration before embedding into Tissue-Tek O.C.T. (Electron 
Microscopy Sciences, Hatfield, PA, USA) and sectioning to 7 or 10 µm sections using a 
cryostat onto Superfrost Plus microscope slides (Thermo Fischer).  Control samples were 
prepared from mouse brain and sciatic nerve. 
4.6.4 Immunohistochemistry 
Samples were permeabilized using 0.3% Triton X-100 (Sigma-Aldrich) in PBS, 
followed by 2 x 2 min washes with PBS before blocking with M.O.M. Mouse IgG 
Blocking Reagent (Vector Laboratories, Burlingame, CA, USA) for one hour.  Samples 
were washed for 2 x 2 min with PBS, and incubated with M.O.M. Diluent (Vector 
Laboratories) for 5 minutes.  All steps so far were performed at room temperature.  
Primary antibodies were then incubated in M.O.M. diluent over night at 4oC according to 
Table 4-1.  The following day, samples were washed five times over 25 min with PBS, 
and secondary antibodies were incubated for one hour at room temperature, at 1:200 
dilution for Cy3-conjugated anti-mouse IgG2b (Jackson Immuno Research Laberatories 
Inc., Avondale, PA), and 1:500 for all AlexaFluor-conjugated antibodies (Thermo Fisher).  
Samples were once again washed 5 times over 25 min with PBS, and then treated with 
Antifluorescence Eliminator Reagent (Millipore, Billerica, MA, USA) according to the 
manufacturer’s protocol and mounted using ProLong Diamond Mounting Reagent with 
DAPI (Thermo Fisher) over night.  Controls where primary antibodies were omitted were 
performed on known positive control samples to account for non-specific binding and 
cross-reactivity.  For antigens normally not found in PNS tissue, mouse brain sections 
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served as positive controls.  Samples were analyzed using a Zeiss LSM 780 scanning 
laser confocal microscope system (Carl Zeiss Microscopy GmbH). 
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